

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in managing and understanding... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-612/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-612" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis.">
            <meta name="og:description" content="Read the latest article version by Akito Hasegawa, Riichiro Abe, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="27302">
            <meta name="article-id" content="24748">
            <meta name="dc.title" content="Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis">
            <meta name="dc.description" content="Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening diseases characterized by detachment of the epidermis and mucous membrane. SJS/TEN are considered to be on the same spectrum of diseases with different severities. They are classified by the percentage of skin detachment area. SJS/TEN can also cause several complications in the liver, kidneys, and respiratory tract. The pathogenesis of SJS/TEN is still unclear. Although it is difficult to diagnose early stage SJS/TEN, biomarkers for diagnosis or severity prediction have not been well established. Furthermore, optimal therapeutic options for SJS/TEN are still controversial. 
Several drugs, such as carbamazepine and allopurinol, are reported to have a strong relationship with a specific human leukocyte antigen (HLA) type. This relationship differs between different ethnicities. Recently, the usefulness of HLA screening before administering specific drugs to decrease the incidence of SJS/TEN has been investigated. 
Skin detachment in SJS/TEN skin lesions is caused by extensive epidermal cell death, which has been considered to be apoptosis via the Fas-FasL pathway or perforin/granzyme pathway. We reported that necroptosis, i.e. programmed necrosis, also contributes to epidermal cell death. Annexin A1, released from monocytes, and its interaction with the formyl peptide receptor 1 induce necroptosis. Several diagnostic or prognostic biomarkers for SJS/TEN have been reported, such as CCL-27, IL-15, galectin-7, and RIP3. 
Supportive care is recommended for the treatment of SJS/TEN. However, optimal therapeutic options such as systemic corticosteroids, intravenous immunoglobulin, cyclosporine, and TNF-&alpha; antagonists are still controversial. Recently, the beneficial effects of cyclosporine and TNF-&alpha; antagonists have been explored. In this review, we discuss recent advances in the pathophysiology and management of SJS/TEN.">
            <meta name="dc.subject" content="Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, drug reaction, necroptosis">
            <meta name="dc.creator" content="Hasegawa, Akito">
            <meta name="dc.creator" content="Abe, Riichiro">
            <meta name="dc.date" content="2020/06/16">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.24748.1">
            <meta name="dc.source" content="F1000Research 2020 9:612">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Stevens-Johnson syndrome">
            <meta name="prism.keyword" content="toxic epidermal necrolysis">
            <meta name="prism.keyword" content="erythema multiforme">
            <meta name="prism.keyword" content="drug reaction">
            <meta name="prism.keyword" content="necroptosis">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/06/16">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="612">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.24748.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-612">
            <meta name="citation_title" content="Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis">
            <meta name="citation_abstract" content="Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening diseases characterized by detachment of the epidermis and mucous membrane. SJS/TEN are considered to be on the same spectrum of diseases with different severities. They are classified by the percentage of skin detachment area. SJS/TEN can also cause several complications in the liver, kidneys, and respiratory tract. The pathogenesis of SJS/TEN is still unclear. Although it is difficult to diagnose early stage SJS/TEN, biomarkers for diagnosis or severity prediction have not been well established. Furthermore, optimal therapeutic options for SJS/TEN are still controversial. 
Several drugs, such as carbamazepine and allopurinol, are reported to have a strong relationship with a specific human leukocyte antigen (HLA) type. This relationship differs between different ethnicities. Recently, the usefulness of HLA screening before administering specific drugs to decrease the incidence of SJS/TEN has been investigated. 
Skin detachment in SJS/TEN skin lesions is caused by extensive epidermal cell death, which has been considered to be apoptosis via the Fas-FasL pathway or perforin/granzyme pathway. We reported that necroptosis, i.e. programmed necrosis, also contributes to epidermal cell death. Annexin A1, released from monocytes, and its interaction with the formyl peptide receptor 1 induce necroptosis. Several diagnostic or prognostic biomarkers for SJS/TEN have been reported, such as CCL-27, IL-15, galectin-7, and RIP3. 
Supportive care is recommended for the treatment of SJS/TEN. However, optimal therapeutic options such as systemic corticosteroids, intravenous immunoglobulin, cyclosporine, and TNF-&alpha; antagonists are still controversial. Recently, the beneficial effects of cyclosporine and TNF-&alpha; antagonists have been explored. In this review, we discuss recent advances in the pathophysiology and management of SJS/TEN.">
            <meta name="citation_description" content="Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening diseases characterized by detachment of the epidermis and mucous membrane. SJS/TEN are considered to be on the same spectrum of diseases with different severities. They are classified by the percentage of skin detachment area. SJS/TEN can also cause several complications in the liver, kidneys, and respiratory tract. The pathogenesis of SJS/TEN is still unclear. Although it is difficult to diagnose early stage SJS/TEN, biomarkers for diagnosis or severity prediction have not been well established. Furthermore, optimal therapeutic options for SJS/TEN are still controversial. 
Several drugs, such as carbamazepine and allopurinol, are reported to have a strong relationship with a specific human leukocyte antigen (HLA) type. This relationship differs between different ethnicities. Recently, the usefulness of HLA screening before administering specific drugs to decrease the incidence of SJS/TEN has been investigated. 
Skin detachment in SJS/TEN skin lesions is caused by extensive epidermal cell death, which has been considered to be apoptosis via the Fas-FasL pathway or perforin/granzyme pathway. We reported that necroptosis, i.e. programmed necrosis, also contributes to epidermal cell death. Annexin A1, released from monocytes, and its interaction with the formyl peptide receptor 1 induce necroptosis. Several diagnostic or prognostic biomarkers for SJS/TEN have been reported, such as CCL-27, IL-15, galectin-7, and RIP3. 
Supportive care is recommended for the treatment of SJS/TEN. However, optimal therapeutic options such as systemic corticosteroids, intravenous immunoglobulin, cyclosporine, and TNF-&alpha; antagonists are still controversial. Recently, the beneficial effects of cyclosporine and TNF-&alpha; antagonists have been explored. In this review, we discuss recent advances in the pathophysiology and management of SJS/TEN.">
            <meta name="citation_keywords" content="Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, drug reaction, necroptosis">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Akito Hasegawa">
            <meta name="citation_author_institution" content="Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan">
            <meta name="citation_author" content="Riichiro Abe">
            <meta name="citation_author_institution" content="Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan">
            <meta name="citation_publication_date" content="2020/06/16">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="612">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.24748.1">
            <meta name="citation_firstpage" content="612">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-612/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-612.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=27302 /> <input type=hidden id=articleId name=articleId value=24748 /> <input type=hidden id=xmlUrl value="/articles/9-612/v1/xml"/> <input type=hidden id=xmlFileName value="-9-612-v1.xml"> <input type=hidden id=article_uuid value=ac77206c-0eeb-4edf-b864-23c5086eab69 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.24748.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.24748.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-612"
  },
  "headline": "Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis",
  "datePublished": "2020-06-16T08:35:09",
  "dateModified": "2020-06-16T08:35:09",
  "author": [
    {
      "@type": "Person",
      "name": "Akito Hasegawa"
    },    {
      "@type": "Person",
      "name": "Riichiro Abe"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening diseases characterized by detachment of the epidermis and mucous membrane. SJS/TEN are considered to be on the same spectrum of diseases with different severities. They are classified by the percentage of skin detachment area. SJS/TEN can also cause several complications in the liver, kidneys, and respiratory tract. The pathogenesis of SJS/TEN is still unclear. Although it is difficult to diagnose early stage SJS/TEN, biomarkers for diagnosis or severity prediction have not been well established. Furthermore, optimal therapeutic options for SJS/TEN are still controversial.
Several drugs, such as carbamazepine and allopurinol, are reported to have a strong relationship with a specific human leukocyte antigen (HLA) type. This relationship differs between different ethnicities. Recently, the usefulness of HLA screening before administering specific drugs to decrease the incidence of SJS/TEN has been investigated.
Skin detachment in SJS/TEN skin lesions is caused by extensive epidermal cell death, which has been considered to be apoptosis via the Fas-FasL pathway or perforin/granzyme pathway. We reported that necroptosis, i.e. programmed necrosis, also contributes to epidermal cell death. Annexin A1, released from monocytes, and its interaction with the formyl peptide receptor 1 induce necroptosis. Several diagnostic or prognostic biomarkers for SJS/TEN have been reported, such as CCL-27, IL-15, galectin-7, and RIP3.
Supportive care is recommended for the treatment of SJS/TEN. However, optimal therapeutic options such as systemic corticosteroids, intravenous immunoglobulin, cyclosporine, and TNF-&alpha; antagonists are still controversial. Recently, the beneficial effects of cyclosporine and TNF-&alpha; antagonists have been explored. In this review, we discuss recent advances in the pathophysiology and management of SJS/TEN."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-612",
            "name": "Recent advances in managing and understanding Stevens-Johnson syndrome..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in managing and understanding Stevens-Johnson syndrome... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=27302 data-id=24748 data-downloads="" data-views="" data-scholar="10.12688/f1000research.24748.1" data-recommended="" data-doi="10.12688/f1000research.24748.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-612/v1/pdf?article_uuid=ac77206c-0eeb-4edf-b864-23c5086eab69" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-24748-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-24748-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-24748-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Hasegawa A and Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):612 (<a class=new-orange href="https://doi.org/10.12688/f1000research.24748.1" target=_blank>https://doi.org/10.12688/f1000research.24748.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-24748-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=24748 id=track-article-signin-24748 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/24748?target=/articles/9-612">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=27302 /> <input name=articleId type=hidden value=24748 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:hakito@med.niigata-u.ac.jp" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Akito Hasegawa</span></a><a href="https://orcid.org/0000-0002-7606-5551" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-7606-5551</div>,&nbsp;</span><span class=""><a href="mailto:aberi@med.niigata-u.ac.jp" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Riichiro Abe</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:hakito@med.niigata-u.ac.jp" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Akito Hasegawa</span></a><a href="http://orcid.org/0000-0002-7606-5551" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-7606-5551</div>,&nbsp;</span><span class=""><a href="mailto:aberi@med.niigata-u.ac.jp" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Riichiro Abe</span></a></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 16 Jun 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.24748.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan<br/> <p> <div class=margin-bottom> Akito Hasegawa <br/> <span>Roles: </span> Conceptualization, Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Riichiro Abe <br/> <span>Roles: </span> Data Curation, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=68826-64515></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=68825-64514></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening diseases characterized by detachment of the epidermis and mucous membrane. SJS/TEN are considered to be on the same spectrum of diseases with different severities. They are classified by the percentage of skin detachment area. SJS/TEN can also cause several complications in the liver, kidneys, and respiratory tract. The pathogenesis of SJS/TEN is still unclear. Although it is difficult to diagnose early stage SJS/TEN, biomarkers for diagnosis or severity prediction have not been well established. Furthermore, optimal therapeutic options for SJS/TEN are still controversial.<br/> Several drugs, such as carbamazepine and allopurinol, are reported to have a strong relationship with a specific human leukocyte antigen (HLA) type. This relationship differs between different ethnicities. Recently, the usefulness of HLA screening before administering specific drugs to decrease the incidence of SJS/TEN has been investigated.<br/> Skin detachment in SJS/TEN skin lesions is caused by extensive epidermal cell death, which has been considered to be apoptosis via the Fas-FasL pathway or perforin/granzyme pathway. We reported that necroptosis, i.e. programmed necrosis, also contributes to epidermal cell death. Annexin A1, released from monocytes, and its interaction with the formyl peptide receptor 1 induce necroptosis. Several diagnostic or prognostic biomarkers for SJS/TEN have been reported, such as CCL-27, IL-15, galectin-7, and RIP3.<br/> Supportive care is recommended for the treatment of SJS/TEN. However, optimal therapeutic options such as systemic corticosteroids, intravenous immunoglobulin, cyclosporine, and TNF-α antagonists are still controversial. Recently, the beneficial effects of cyclosporine and TNF-α antagonists have been explored. In this review, we discuss recent advances in the pathophysiology and management of SJS/TEN. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, drug reaction, necroptosis </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Akito Hasegawa (<a href="mailto:hakito@med.niigata-u.ac.jp">hakito@med.niigata-u.ac.jp</a>) <br> Riichiro Abe (<a href="mailto:aberi@med.niigata-u.ac.jp">aberi@med.niigata-u.ac.jp</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding authors:</b> Akito Hasegawa, Riichiro Abe </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Hasegawa A and Abe R. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Hasegawa A and Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):612 (<a href="https://doi.org/10.12688/f1000research.24748.1" target=_blank>https://doi.org/10.12688/f1000research.24748.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 16 Jun 2020, <b>9</b>(F1000 Faculty Rev):612 (<a href="https://doi.org/10.12688/f1000research.24748.1" target=_blank>https://doi.org/10.12688/f1000research.24748.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 16 Jun 2020, <b>9</b>(F1000 Faculty Rev):612 (<a href="https://doi.org/10.12688/f1000research.24748.1" target=_blank>https://doi.org/10.12688/f1000research.24748.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d32611e162>Introduction</h2><p class="" id=d32611e165>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe and life-threatening mucocutaneous reactions characterized by blisters and skin detachment. Drugs and infection, such as by <i>Mycoplasma</i> or the herpes simplex virus, are the main causes<sup><a href="#ref-1">1</a></sup>.</p><p class="" id=d32611e175>SJS/TEN are considered to be on the same spectrum of diseases with different severities. They are classified by the percentage of skin detachment area (<a href="#T1">Table 1</a>)<sup><a href="#ref-2">2</a></sup>. Although a study in the USA indicated that the incidence rate is 1.58 to 2.26 cases/million people, the overall incidence of SJS/TEN remains unclear. Contrary to its low incidence rate, the mortality rate is high (SJS: 4.8%, TEN: 14.8%)<sup><a href="#ref-3">3</a></sup>. Furthermore, even after recovery, sequelae such as blindness remain in some cases<sup><a href="#ref-1">1</a></sup>. Thus, patients with SJS/TEN should be accurately diagnosed, and appropriate treatment should commence as soon as possible. Therefore, a biomarker for early diagnosis and severity prediction is necessary. Further issues include the lack of evidence regarding the adequate management of SJS/TEN.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Classification of SJS/TEN.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d32611e204 class=n-a></a><thead><a name=d32611e206 class=n-a></a><tr><a name=d32611e208 class=n-a></a><th align=center colspan=1 rowspan=1><a name=d32611e210 class=n-a></a>Diagnosis</th><th align=center colspan=1 rowspan=1><a name=d32611e213 class=n-a></a>Skin detachment area (%)</th></tr></thead><tbody><a name=d32611e218 class=n-a></a><tr><a name=d32611e220 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d32611e222 class=n-a></a>SJS</td><td align=center colspan=1 rowspan=1><a name=d32611e225 class=n-a></a>&lt;10</td></tr><tr><a name=d32611e229 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d32611e231 class=n-a></a>SJS/TEN overlap</td><td align=center colspan=1 rowspan=1><a name=d32611e234 class=n-a></a>10–30</td></tr><tr><a name=d32611e238 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d32611e240 class=n-a></a>TEN</td><td align=center colspan=1 rowspan=1><a name=d32611e243 class=n-a></a>&gt;30</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d32611e251 class=n-a></a><p id=d32611e253> SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis</p></div></div></div><p class="" id=d32611e259>In this review, we describe recent advances in the research and management of SJS/TEN.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d32611e265>Clinical features</h2><p class="" id=d32611e268>The cutaneous symptoms for SJS/TEN are a painful erythematous rash, bullae, and erosion appearing on the face and trunk and spreading to the extremities. The early skin lesions appear as round lesions with only two nonpalpable zones with an indistinct border and are called “atypical targets”. Skin lesions typically test positive for the Nikolsky sign, which manifests with skin erosion upon gentle pressure<sup><a href="#ref-4">4</a></sup>. Malaise, fever, and upper respiratory tract symptoms often precede the onset of the skin rash by a few days. Almost all patients with SJS/TEN develop mucosal involvement of the eyes, mouth, and genitalia<sup><a href="#ref-5">5</a></sup>. The involvement of the eyes often relates to sequelae such as dry eyes, visual acuity, conjunctivitis, corneal erosions, and trichiasis. In severe cases, ocular sequelae can reach as far as blindness.</p><p class="" id=d32611e279>The severity-of-illness score for TEN (SCORTEN) is widely used to predict mortality for SJS/TEN<sup><a href="#ref-6">6</a></sup>. SCORTEN should be assessed within the first 24 hours after admission and again on day 3. SCORTEN is based on seven independent risk factors (<a href="#T2">Table 2</a>). The more risk factors that are present, the higher the mortality rate (<a href="#T3">Table 3</a>).</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Risk factors for SCORTEN.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d32611e303 class=n-a></a><tbody><a name=d32611e305 class=n-a></a><tr><a name=d32611e307 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d32611e309 class=n-a></a>Age over 40 years</td></tr><tr><a name=d32611e313 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d32611e315 class=n-a></a>Heart rate &gt;120 beats per minute</td></tr><tr><a name=d32611e319 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d32611e321 class=n-a></a>Presence of cancer or hematologic malignancy</td></tr><tr><a name=d32611e325 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d32611e327 class=n-a></a>Epidermal detachment area involving body surface area &gt;10%</td></tr><tr><a name=d32611e331 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d32611e333 class=n-a></a>Blood urea nitrogen &gt;28 mg/dL (10 mmol/L)</td></tr><tr><a name=d32611e338 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d32611e340 class=n-a></a>Blood glucose &gt;252 mg/dL (14 mmol/L)</td></tr><tr><a name=d32611e344 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d32611e346 class=n-a></a>Bicarbonate &lt;20 mEq/L</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d32611e354 class=n-a></a><p id=d32611e356> SCORTEN, Score of Toxic Epidermal Necrosis</p></div></div></div><a name=T3 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 3. Mortality rate in SCORTEN.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d32611e373 class=n-a></a><thead><a name=d32611e375 class=n-a></a><tr><a name=d32611e377 class=n-a></a><th align=center colspan=1 rowspan=1><a name=d32611e379 class=n-a></a>Number of risk factors</th><th align=center colspan=1 rowspan=1><a name=d32611e382 class=n-a></a>Mortality rate (%)</th></tr></thead><tbody><a name=d32611e387 class=n-a></a><tr><a name=d32611e389 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d32611e391 class=n-a></a>0–1</td><td align=center colspan=1 rowspan=1><a name=d32611e394 class=n-a></a>3.2</td></tr><tr><a name=d32611e398 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d32611e400 class=n-a></a>2</td><td align=center colspan=1 rowspan=1><a name=d32611e403 class=n-a></a>12.1</td></tr><tr><a name=d32611e407 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d32611e409 class=n-a></a>3</td><td align=center colspan=1 rowspan=1><a name=d32611e412 class=n-a></a>35.3</td></tr><tr><a name=d32611e416 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d32611e418 class=n-a></a>4</td><td align=center colspan=1 rowspan=1><a name=d32611e421 class=n-a></a>58.3</td></tr><tr><a name=d32611e425 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d32611e427 class=n-a></a>≥5</td><td align=center colspan=1 rowspan=1><a name=d32611e430 class=n-a></a>90</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d32611e438 class=n-a></a><p id=d32611e440> SCORTEN, Score of Toxic Epidermal Necrosis</p></div></div></div><p class="" id=d32611e447>SJS/TEN are mainly drug-induced diseases. The most frequently causative drugs include antibiotics, allopurinol, non-steroidal anti-inflammatory drugs, and antiepileptic drugs (<a href="#T4">Table 4</a>)<sup><a href="#ref-7">7</a></sup>.</p><a name=T4 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 4. Medications associated with high risk of SJS/TEN.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d32611e468 class=n-a></a><tbody><a name=d32611e470 class=n-a></a><tr><a name=d32611e472 class=n-a></a><td align=center colspan=1 rowspan=1 valign=top><a name=d32611e474 class=n-a></a>Nevirapine</td></tr><tr><a name=d32611e478 class=n-a></a><td align=center colspan=1 rowspan=1 valign=top><a name=d32611e480 class=n-a></a>Lamotrigine</td></tr><tr><a name=d32611e484 class=n-a></a><td align=center colspan=1 rowspan=1 valign=top><a name=d32611e486 class=n-a></a>Carbamazepine</td></tr><tr><a name=d32611e490 class=n-a></a><td align=center colspan=1 rowspan=1 valign=top><a name=d32611e492 class=n-a></a>Phenytoin</td></tr><tr><a name=d32611e496 class=n-a></a><td align=center colspan=1 rowspan=1 valign=top><a name=d32611e498 class=n-a></a>Cotrimoxazole and other anti-infective sulfonamides</td></tr><tr><a name=d32611e503 class=n-a></a><td align=center colspan=1 rowspan=1 valign=top><a name=d32611e505 class=n-a></a>Sulfasalazine</td></tr><tr><a name=d32611e509 class=n-a></a><td align=center colspan=1 rowspan=1 valign=top><a name=d32611e511 class=n-a></a>Allopurinol</td></tr><tr><a name=d32611e515 class=n-a></a><td align=center colspan=1 rowspan=1 valign=top><a name=d32611e517 class=n-a></a>Oxicam/NSAIDs</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=tfn1 class=n-a></a><p id=d32611e527> NSAID, non-steroidal anti-inflammatory drug; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d32611e536>Genetic factors</h2><p class="" id=d32611e539>There is increasing evidence of a genetic contribution to the incidence of cutaneous adverse reactions. In 2004, Chung <i>et al.</i> reported on a strong relationship between human leukocyte antigen (HLA)-B*15:02 and carbamazepine (CBZ)-induced SJS/TEN in a Han Chinese population<sup><a href="#ref-8">8</a></sup>. HLA alleles are divided into class I and class II, and they are specialized to present antigenic peptides to T cells, resulting in the activation of the immune response. In this study, 44 patients with CBZ-induced SJS/TEN were included, and all patients had the HLA-B*15:02 allele (100%). Following this, similar studies reported the relationship between CBZ-induced SJS/TEN and the HLA-B*15:02 allele in Asian populations including those in China, Thailand, Malaysia, and India<sup><a href="#ref-9">9</a>–<a href="#ref-20">20</a></sup>.</p><p class="" id=d32611e556>The relationship between SJS/TEN and HLA-B*15:02 has also been demonstrated in aromatic antiepileptic drugs other than CBZ. Although the incidence was lower than that seen with CBZ, HLA-*15:02 showed a strong association with phenytoin-, lamotrigine-, and oxcarbazepine-induced SJS/TEN<sup><a href="#ref-11">11</a>,<a href="#ref-21">21</a>–<a href="#ref-25">25</a></sup>. Conversely, there was no association between CBZ-induced SJS/TEN and HLA-B*15:02 in Japanese, Korean, and European populations<sup><a href="#ref-26">26</a>–<a href="#ref-32">32</a></sup>.</p><p class="" id=d32611e576>Ozeki <i>et al.</i> discovered that HLA-A*31:01 is also associated with CBZ-induced SJS/TEN<sup><a href="#ref-33">33</a></sup>. HLA-A*31:01 revealed a relationship with CBZ-induced SJS/TEN not only in Japanese but also in Korean and European populations<sup><a href="#ref-14">14</a>,<a href="#ref-32">32</a>,<a href="#ref-34">34</a>,<a href="#ref-35">35</a></sup>. Although the majority of CBZ-induced SJS/TEN is associated with HLA-B*15:02 in Asian populations, the association with HLA-A*31:01 is shown in multiethnic populations. Thus, the HLA association in SJS/TEN is different among different ethnicities.</p><p class="" id=d32611e599>In 2008, the US Food and Drug Administration released a recommendation to perform HLA-B*15:02 genotyping before administering CBZ<sup><a href="#ref-36">36</a></sup>. In Taiwan, it is reported that HLA-B*15:02 screening is strongly associated with a decrease in the incidence of CBZ-induced SJS/TEN<sup><a href="#ref-37">37</a></sup>.</p><p class="" id=d32611e611>As well as antiepileptic drugs, several other drugs, such as allopurinol and abacavir, have been reported to have HLA associations. Allopurinol is an anti-hyperuricemia drug which is a major cause of SJS/TEN. The relationship between HLA-B*58:01 and allopurinol-induced SJS/TEN has been reported in many ethnicities, including in Taiwanese, Japanese, Korean, Thai, and European individuals<sup><a href="#ref-26">26</a>,<a href="#ref-28">28</a>,<a href="#ref-30">30</a>,<a href="#ref-38">38</a>–<a href="#ref-45">45</a></sup>. Therefore, these data suggested that HLA-B*58:01 genotyping may be useful to prevent allopurinol-induced SJS/TEN.</p><p class="" id=d32611e630>Cost-effectiveness analysis of HLA-B*58:01 screening in Taiwan suggested a cost-saving effect in preventing allopurinol-induced SJS/TEN<sup><a href="#ref-46">46</a></sup>. In a US study, it was suggested that testing for HLA-B*5801 prior to allopurinol initiation is cost effective for Asians and African Americans but not for Caucasians or Hispanics<sup><a href="#ref-47">47</a></sup>.</p><p class="" id=d32611e641>Abacavir, a nucleoside reverse transcriptase inhibitor used to treat HIV infection, is reported to induce SJS/TEN in patients carrying HLA-B*57:01<sup><a href="#ref-48">48</a>–<a href="#ref-52">52</a></sup>. In 2008, HLA-B*57:01 screening was added to clinical care guidelines to reduce the risk of hypersensitivity reaction from abacavir<sup><a href="#ref-53">53</a></sup>. The frequency of HLA-B*57:01 screening then increased steadily, and the incidence of abacavir-induced SJS/TEN was decreased<sup><a href="#ref-54">54</a></sup>. However, many patients have not undergone HLA-B*57:01 screening. The expansion of HLA*B-57:01 screening is expected to reduce the incidence of abacavir-induced SJS/TEN.</p><p class="" id=d32611e659>Cytochrome P (CYP) is also an important genetic factor. CYPs are involved in drug metabolism. CYP450 genes have 57 variants, and each variant shows functional differences. Patients whose drug metabolism is slow because of CYP450 variants have a high risk of developing adverse drug reactions<sup><a href="#ref-55">55</a></sup>. Chung <i>et al.</i> discovered specific genetic factors associated with phenytoin-induced SJS/TEN<sup><a href="#ref-56">56</a></sup>. In this study, 16 significant single nucleotide polymorphisms in CYP2C9 were identified. Patients with phenytoin-induced SJS/TEN who had CYP2C9*3 showed a delayed clearance of phenytoin, resulting in increased disease severity.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d32611e676>Pathogenesis and diagnostic biomarkers</h2><div class=section><a name=d32611e679 class=n-a></a><h3 class=section-title>Immunopathogenesis</h3><p class="" id=d32611e684>SJS/TEN is traditionally thought to be a T-cell-mediated disorder. T cells are activated by binding of drugs to T cell receptors (TCRs) from antigen-presenting cells (APCs). There are currently three hypotheses on T cell activation<sup><a href="#ref-57">57</a>–<a href="#ref-59">59</a></sup> (<a href="#f1">Figure 1</a>): (1) the hapten/pro-hapten model, (2) the pharmacological interaction (p-i) concept, and (3) the altered peptide model. The majority of drugs and their metabolites are pro-haptens and do not act as haptens themselves. They acquire the immunogenicity by covalently binding to carrier proteins (hapten antigen). Hapten antigens form a complex with HLA in APCs and are recognized by TCRs. This stimulation triggers the drug-specific T cell activation. In this model, antigenic drugs are covalently bound to peptides presented by HLA molecules to TCRs<sup><a href="#ref-60">60</a>–<a href="#ref-63">63</a></sup>. However, some drugs can non-covalently bind directly to HLA and/or TCRs. This type of binding is termed the p-i concept. CBZ, lamotrigine, sulfamethoxazole, and celecoxib are known to fit this model<sup><a href="#ref-64">64</a>–<a href="#ref-68">68</a></sup>. In general, HLA polymorphisms are dependent on the antigen-binding cleft. It has been reported that unmodified abacavir binds to the antigen-binding cleft lying in the bottom of HLA-B*57:01 and changes the shape and chemistry of the antigen-binding cleft, altering the repertoire of endogenous peptides that can bind HLA-B*57:01 (altered peptide)<sup><a href="#ref-69">69</a>,<a href="#ref-70">70</a></sup>. The TCR profile is also associated with the development of SJS/TEN. Ko <i>et al.</i> identified the VB-11-ISGSY clonotype in 84% of patients with CBZ-associated SJS/TEN<sup><a href="#ref-71">71</a>,<a href="#ref-72">72</a></sup>. This clonotype was not present in CBZ-tolerant patients. The clonotype specificity is also reported in oxypurinol-induced SJS/TEN<sup><a href="#ref-73">73</a></sup>. Recently, Pan <i>et al.</i> investigated the TCR repertoire through next-generation sequencing and identified a public αβTCR from the cytotoxic T cells of patients with CBZ-induced SJS/TEN. This public αβTCR can bind with CBZ and mediate an immune response<sup><a href="#ref-74">74</a></sup>.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/27302/74ba1955-9f89-4423-bfe1-5e54bf29aa8e_figure1.gif"><img alt="74ba1955-9f89-4423-bfe1-5e54bf29aa8e_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/27302/74ba1955-9f89-4423-bfe1-5e54bf29aa8e_figure1.gif"></a><div class=caption><h3>Figure 1. Models of T cell activation in Stevens-Johnson syndrome/toxic epidermal necrolysis.</h3><p id=d32611e750>(<b>A</b>) Hapten/pro-hapten model: drugs or drug metabolites form a complex with carrier proteins and are presented as haptenated peptides in the peptide-binding groove of the HLA molecules. (<b>B</b>) p-i concept: drugs directly bind to HLA and TCR non-covalently. (<b>C</b>) Altered peptide model: drugs bind to the peptide-binding groove of HLA, resulting in the alteration of the HLA-binding peptide repertoire. APC, antigen-presenting cell; HLA, human leukocyte antigen; TCR, T cell receptor.</p></div></div><p class="" id=d32611e766>In the early stages of the disease, cytotoxic CD8<sup>+</sup> T cells mainly infiltrate blister fluid and the epidermis, and CD4<sup>+</sup> T cells mostly infiltrate the dermis<sup><a href="#ref-75">75</a>,<a href="#ref-76">76</a></sup>. Monocytes are present in the epidermis of TEN patients. In the later stages, lymphocytes are decreased and an increased number of monocytes is observed. Tohyama <i>et al.</i> reported that monocytes play an important role in epidermal damage, probably by enhancing the cytotoxicity of CD8<sup>+</sup> T cells<sup><a href="#ref-77">77</a></sup>. In the serum and blister fluid of SJS/TEN patients, increased levels of soluble IL-2 receptors were observed<sup><a href="#ref-78">78</a></sup>. Soluble IL-2 receptors are a marker for activated T cells, indicating the importance of activated cytotoxic CD8<sup>+</sup> T cells in the pathogenesis of SJS/TEN.</p></div><div class=section><a name=d32611e801 class=n-a></a><h3 class=section-title>Keratinocyte death</h3><p class="" id=d32611e806>The epidermal damage in the skin lesions of SJS/TEN patients is considered to be of apoptotic origin<sup><a href="#ref-79">79</a></sup>. Apoptosis is induced by cytotoxic CD8<sup>+</sup> T cells through the Fas-Fas ligand (FasL) pathway or the perforin/granzyme pathway<sup><a href="#ref-80">80</a></sup>.</p><p class="" id=d32611e820>Cytotoxic CD8<sup>+</sup> T cells and natural killer (NK) cells produce FasL, which binds Fas on target cells. Recognition of FasL causes activation of the caspase cascade and the resulting cells undergo apoptosis<sup><a href="#ref-80">80</a></sup>. Under normal conditions, Fas is present on the surface of keratinocytes and FasL is expressed intracellularly. FasL is transported to the cell surface when the cell needs to self-destruct<sup><a href="#ref-81">81</a></sup>. Viard <i>et al.</i> demonstrated that the cell surface of keratinocytes of TEN patients has FasL on it but not the keratinocytes of patients with maculopapular drug reactions<sup><a href="#ref-82">82</a></sup>. In addition, high levels of soluble FasL (sFasL) were found in the serum of TEN patients. sFasL also has the potential to mediate apoptosis<sup><a href="#ref-83">83</a></sup>.</p><p class="" id=d32611e846>We showed that FasL serum levels increased in patients with TEN<sup><a href="#ref-84">84</a>,<a href="#ref-85">85</a></sup>. This study revealed that sFasL was produced by peripheral blood mononuclear cells (PBMCs) when the causative drugs were added. sFasL released from PBMCs binds to Fas expressed on keratinocytes to cause apoptosis. This study suggested that elevated levels of serum sFasL may be a useful diagnostic marker for SJS/TEN. However, a correlation between sFasL levels and disease severity has not been established<sup><a href="#ref-84">84</a>,<a href="#ref-86">86</a></sup>.</p><p class="" id=d32611e863>Nassif <i>et al.</i> emphasized the importance of the perforin/granzyme pathway<sup><a href="#ref-87">87</a>,<a href="#ref-88">88</a></sup>. Upon recognition of a target cell, the cytotoxic CD8<sup>+</sup> T cell releases perforin and granzyme B<sup><a href="#ref-80">80</a></sup>. This study revealed that mononuclear cells in the blister fluid of TEN patients have cytotoxic effects in the presence of a causative drug. This cytotoxicity is blocked by the perforin/granzyme pathway inhibitor. These findings suggest that the perforin/granzyme pathway causes epidermal damage in the skin lesions of SJS/TEN<sup><a href="#ref-87">87</a>,<a href="#ref-88">88</a></sup>.</p><p class="" id=d32611e891>In 2008, Chung <i>et al.</i> demonstrated the cytotoxic effect of granulysin in SJS/TEN<sup><a href="#ref-89">89</a></sup>. Granulysin is a pro-apoptotic protein which permits cell-mediated cytotoxicity without direct cell-to-cell contact. In SJS/TEN blisters, high levels of granulysin are detected. Granulysin is released from blister cells in skin lesions of SJS/TEN including cytotoxic CD8<sup>+</sup> T cell and NK cells. The severity of the cutaneous lesions correlated with serum granulysin levels. We also reported granulysin as an early diagnostic marker<sup><a href="#ref-90">90</a></sup>. However, serum granulysin levels are also elevated in patients with drug-induced hypersensitivity syndrome/drug reactions with eosinophilia and systemic symptoms, which are other types of severe cutaneous adverse drug reaction characterized by a viral infection<sup><a href="#ref-91">91</a></sup>. Therefore, it is difficult to use granulysin as an SJS/TEN-specific biomarker.</p><p class="" id=d32611e912>In 2014, we reported that necroptosis induced by annexin A1–formyl peptide receptor 1 (FPR1) interaction contributes to keratinocyte death in SJS/TEN<sup><a href="#ref-92">92</a></sup>. Necroptosis is a type of programmed cell death which reveals morphological necrosis. Necroptotic cells release damage-associated molecular patterns (DAMPs), including a range of pro-inflammatory cytokines, resulting in inflammation, unlike apoptosis. Apoptotic cells are quickly phagocytosed by macrophages and degraded within phagolysosomes. No inflammatory reaction occurs with the process of apoptosis or with the removal of apoptotic cells<sup><a href="#ref-93">93</a></sup>. In general, necroptosis occurs through the stimulation of TNF-α under conditions in which apoptosis is blocked. In TNF-α stimulation, receptor interacting kinase 1 (RIP1) and receptor interacting kinase 3 (RIP3) are phosphorylated and form a “necrosome” complex. Furthermore, the mixed lineage kinase domain-like (MLKL) pseudokinase is recruited to the necrosome and phosphorylated by RIP3. The phosphorylated MLKL (pMLKL) is localized to the plasma membrane and induces cell death<sup><a href="#ref-93">93</a></sup>. Supernatant from PBMCs, which are exposed to the causative drug in SJS/TEN patients, induces the death of SJS/TEN keratinocytes. This cytotoxicity is blocked by necrostatin-1, a specific inhibitor of RIP1. In SJS/TEN skin lesions, keratinocytes express abundant FPR1 and monocytes secrete annexin A1. The interaction of annexin A1 and FPR1 induces necrosome formation (<a href="#f2">Figure 2</a>). Inhibition of necroptosis completely prevents SJS/TEN-like responses in a mouse model of SJS/TEN<sup><a href="#ref-92">92</a>,<a href="#ref-94">94</a></sup>. Therefore, these results suggest that necroptosis plays an important role in the pathogenesis of SJS/TEN.</p><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/27302/74ba1955-9f89-4423-bfe1-5e54bf29aa8e_figure2.gif"><img alt="74ba1955-9f89-4423-bfe1-5e54bf29aa8e_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/27302/74ba1955-9f89-4423-bfe1-5e54bf29aa8e_figure2.gif"></a><div class=caption><h3>Figure 2. Necroptosis pathway in Stevens-Johnson syndrome/toxic epidermal necrolysis.</h3><p id=d32611e947>Drug-stimulated monocytes secrete annexin A1. Annexin A1 binds to FPR1, RIP1 and RIP3 form the necrosome, and MLKL is phosphorylated by RIP3. Phosphorylated MLKL translocates to the plasma membrane and induces cell death. FPR1, formyl peptide receptor 1; MLKL, mixed lineage kinase domain-like; RIP1, receptor interacting kinase 1.</p></div></div></div><div class=section><a name=d32611e955 class=n-a></a><h3 class=section-title>Diagnostic biomarkers</h3><p class="" id=d32611e960>Although SJS/TEN is a severe disease, clinical manifestations of early stage SJS/TEN are occasionally undistinguishable from those of maculopapular exanthema and erythema multiforme. However, useful biomarkers for the diagnosis or the prediction of severity have not been well established. Recently, some researchers discovered useful diagnostic or prognostic biomarkers for SJS/TEN. These biomarkers are now in the research phase and have not been used in the clinic yet.</p><p class="" id=d32611e963>Wang <i>et al.</i> revealed an increased concentration of CCL-27 in the serum of SJS/TEN patients, which correlated with disease activity<sup><a href="#ref-95">95</a>,<a href="#ref-96">96</a></sup>. CCL-27 is reported to be associated with cutaneous inflammatory diseases by regulating the trafficking of T cells to the skin<sup><a href="#ref-97">97</a></sup>. Tapia <i>et al.</i> found CCL-27 was highly expressed in the skin lesions of SJS/TEN patients<sup><a href="#ref-98">98</a></sup>. Wang <i>et al.</i> hypothesized that CCL-27 is produced by keratinocytes in the skin lesions found in SJS/TEN and released into the circulation.</p><p class="" id=d32611e991>Su <i>et al.</i> reported that interleukin-15 (IL-15) is associated with mortality and severity in SJS/TEN by measuring 28 serological factors using multiplex immunoassay or ELISA<sup><a href="#ref-99">99</a></sup>. They also revealed that IL-15 contributes to TEN severity by enhancing NK- and T-cell-mediated responses. IL-15 is known to induce the production of TNF-α and downstream cytokines/chemokines<sup><a href="#ref-100">100</a></sup>. The elevation of many cytokines/chemokines in SJS/TEN might be a secondary effect derived from IL-15.</p><p class="" id=d32611e1005>We identified galectin-7 as a diagnostic biomarker using proteomics analysis<sup><a href="#ref-101">101</a></sup>. We hypothesized that certain soluble factors could be secreted only by drug-specific lymphocytes in SJS/TEN patients and not in those with a non-severe cutaneous adverse drug reaction. Hence, these soluble factors could be biomarkers for SJS/TEN. PBMCs from patients with SJS/TEN were cultured with the causative drugs and supernatant was collected. The elevated proteins in the supernatant underwent proteomic analysis<sup><a href="#ref-102">102</a></sup>. Hama, Nishimura, and colleagues concluded that this method allowed for the identification of new SJS/TEN-specific biomarkers that are not known to be associated with the pathogenesis of this condition.</p><p class="" id=d32611e1017>Very recently, we focused on the mechanisms of epidermal necroptosis and identified serum RIP3 as a key mediator of necroptosis and as a diagnostic and severity marker<sup><a href="#ref-103">103</a></sup>. It is reported that the expression of RIP3 increased in cells undergoing necroptosis<sup><a href="#ref-104">104</a></sup>. We revealed that the expression of RIP3 increased in necroptotic keratinocytes as well, and the levels of serum RIP3 were high in the acute phase of patients with SJS/TEN. We also indicated that serum RIP3 levels may correlate with disease activity.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d32611e1032>Management</h2><p class="" id=d32611e1035>In SJS/TEN patients, the epidermal and mucosal membranes are predominantly affected. However, SJS/TEN can also cause complications in several organs, such as the liver, kidneys, and respiratory tract. Thus, multidisciplinary assessment and early management in a specialized hospital environment are key for improving mortality.</p><p class="" id=d32611e1038>Immediate discontinuation of suspected causative drugs is crucial in the initial management of SJS/TEN. In addition, supportive care including fluid replacement<sup><a href="#ref-105">105</a></sup>, nutritional assessment<sup><a href="#ref-106">106</a></sup>, pain relief<sup><a href="#ref-107">107</a></sup>, and supplemental oxygen is necessary. Since infection from skin detachment is a common complication in SJS/TEN patients and it is associated with the impairment of re-epithelialization and may lead to sepsis, daily skin care should be performed. Antibiotic treatment should be given when cutaneous infection is clinically suspected<sup><a href="#ref-108">108</a></sup>.</p><p class="" id=d32611e1057>The optimal therapeutic strategy in SJS/TEN is still controversial<sup><a href="#ref-109">109</a></sup>. Although there have been some reports of benefits with the use of systemic corticosteroids, intravenous immunoglobulins (IVIGs), cyclosporine, TNF-α antagonists (infliximab and etanercept), and plasmapheresis (PP)<sup><a href="#ref-110">110</a>,<a href="#ref-111">111</a></sup>, evidence for systemic treatment is still insufficient. UK guidelines for the management of SJS/TEN, published in 2016, concluded that withdrawal of the culprit drug and multidisciplinary supportive care are prioritized over systemic treatment because of the lack of evidence to demonstrate the benefits of the latter<sup><a href="#ref-112">112</a></sup>. However, in Japanese guidelines for SJS/TEN, published in 2016, systemic treatment is prioritized over supportive care alone. This guideline recommended early initiation of systemic corticosteroid therapy as a first-line treatment. A combination of IVIG or PP therapy is added to systemic corticosteroid therapy if the clinical symptoms are severe or the disease is refractory to systemic corticosteroid alone.</p><p class="" id=d32611e1075>The efficacy of systemic therapy may depend on the disease phase. For example, in the acute phase, immunosuppressive treatments are considered to be suitable since a strong inflammation-like “cytokine storm” occurs in the patient. However, at the peak period during which wide skin detachment develops, strong immunosuppressive treatment may avoid re-epithelization and increase the risk of infection. Previous studies have not considered this point and included all phase results, leading to discrepant results. We introduce each treatment below.</p><div class=section><a name=d32611e1079 class=n-a></a><h3 class=section-title>Systemic corticosteroids</h3><p class="" id=d32611e1084>Previous studies revealed that treatment with corticosteroids in SJS/TEN patients increased the risk of infection and overall complications, including higher mortality<sup><a href="#ref-113">113</a>–<a href="#ref-115">115</a></sup>. Analyses and systematic reviews have not revealed a survival advantage of systemic corticosteroids<sup><a href="#ref-116">116</a>–<a href="#ref-118">118</a></sup>.</p><p class="" id=d32611e1101>However, recent studies suggested a beneficial role for corticosteroid treatment. A European multicenter retrospective study and recent meta-analysis of observational studies showed the beneficial effects of corticosteroids<sup><a href="#ref-110">110</a>,<a href="#ref-119">119</a></sup>. An observational study<i></i> reported that the short-term use of high-dose corticosteroids in the early stages of SJS/TEN reduced mortality without increasing the risk of infection<sup><a href="#ref-120">120</a></sup>. Since cutaneous infection is the most important point in the use of corticosteroids for SJS/TEN patients, short-term use of corticosteroids, improvement of infection control, and wound management are necessary to decrease the mortality rate.</p></div><div class=section><a name=d32611e1118 class=n-a></a><h3 class=section-title>IVIG</h3><p class="" id=d32611e1123>IVIG has been widely used for patients with SJS/TEN. However, the mechanisms of IVIG treatment remain unknown. While some case reports concluded that IVIG did not confer a beneficial effect in decreasing mortality<sup><a href="#ref-121">121</a>–<a href="#ref-123">123</a></sup>, there are some reports which revealed that IVIG had some beneficial effects for patients with SJS/TEN<sup><a href="#ref-124">124</a>–<a href="#ref-128">128</a></sup>. In the largest retrospective study in this field, the European Study of Severe Cutaneous Adverse Reactions (EuroSCAR), IVIG did not improve mortality compared with supportive care alone<sup><a href="#ref-119">119</a></sup>. However, recent meta-analyses have shown that high-dose IVIG (&lt;2 g/kg) has a beneficial effect in decreasing the mortality of SJS/TEN<sup><a href="#ref-129">129</a></sup>. Thus, the use of IVIG for SJS/TEN patients is still controversial. Randomized controlled trials are required.</p></div><div class=section><a name=d32611e1149 class=n-a></a><h3 class=section-title>Cyclosporine</h3><p class="" id=d32611e1154>Cyclosporine, a calcineurin inhibitor, has been reported to have a therapeutic benefit in SJS/TEN. Cyclosporine affects T-lymphocyte-mediated cytotoxicity and inhibits FasL, nuclear factor-kB, and TNF-α<sup><a href="#ref-130">130</a></sup>. Some case reports and meta-analyses have shown that cyclosporine treatment improved mortality in SJS/TEN patients<sup><a href="#ref-131">131</a>–<a href="#ref-138">138</a></sup>. Gilbert and Scherrer reported that cyclosporine appears to have not only a mortality benefit in the treatment of SJS/TEN but also few side effects<sup><a href="#ref-139">139</a></sup>. These data support a potential role for cyclosporine in the treatment of SJS/TEN. However, the number of reported patients is small. Further studies are required to validate the efficacy of cyclosporine.</p></div><div class=section><a name=d32611e1173 class=n-a></a><h3 class=section-title>Plasmapheresis</h3><p class="" id=d32611e1178>Several case series have shown that PP is effective for the treatment of SJS/TEN<sup><a href="#ref-140">140</a>–<a href="#ref-145">145</a></sup>. The purpose of PP is to remove pathogenic factors such as a drug, drug metabolites, and disease-induced cytokines/chemokines from the patient’s blood. PP sessions are carried out every other day or daily. PP is a safe treatment and can be performed with few adverse side effects. Although one observational study has concluded PP treatment to be ineffective, the overall survival in this study was 87.5%<sup><a href="#ref-146">146</a></sup>. Narita <i>et al.</i> reported that PP was effective in TEN patients who were refractory to supportive therapy or systemic corticosteroid therapy and revealed that cytokine serum levels decreased after PP<sup><a href="#ref-147">147</a></sup>.</p><p class="" id=d32611e1199>A study suggested a beneficial effect of combined PP and IVIG therapy<sup><a href="#ref-148">148</a></sup>. However, another study reported negative results for the combined therapy while treatment with PP alone revealed a good result<sup><a href="#ref-149">149</a></sup>. Randomized studies are needed to further define its usefulness.</p></div><div class=section><a name=d32611e1211 class=n-a></a><h3 class=section-title>Tumor necrosis factor inhibitors</h3><p class="" id=d32611e1216>Owing to the skin lesions and blister fluid in SJS/TEN containing high levels of TNF-α<sup><a href="#ref-150">150</a>,<a href="#ref-151">151</a></sup>, TNF-α inhibitors such as etanercept and infliximab have been used and, in some cases, beneficial effects have been suggested<sup><a href="#ref-152">152</a>–<a href="#ref-159">159</a></sup>. However, only a small number of cases have reported the use of TNF-α inhibitors for SJS/TEN. Additional studies are required to confirm the efficacy of these drugs in the treatment of SJS/TEN.</p></div><div class=section><a name=d32611e1234 class=n-a></a><h3 class=section-title>Future directions</h3><p class="" id=d32611e1239>Rapid withdrawal of the culprit drug and intensive supportive care are the basis of treatment for SJS/TEN. The use of systemic corticosteroids and IVIG is still controversial. However, recently, there has been an increasing number of studies suggesting the efficacy of cyclosporine or TNF-α inhibitors. Accumulating evidence of these treatments is desirable. In addition, the pathogenesis of SJS/TEN has been elucidated. It is hoped that this research will lead to the discovery of new therapeutic targets.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d32611e1247>Conclusions</h2><p class="" id=d32611e1250>This review summarizes recent advances in the pathophysiology, diagnosis, and treatment of SJS/TEN. SJS/TEN is a severe disease which has a high mortality rate. However, its diagnostic method and treatment algorithm have not been well established. Further studies to elucidate the pathogenesis of SJS/TEN are needed.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d32611e1257 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading is-hidden"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d33648>References</h2><div class="section ref-list"><a name=d32611e1257 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d32611e1264 class=n-a></a>Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, <i> et al.</i>: Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>Clin Rev Allergy Immunol.</i> 2018; <b>54</b>(1): 147–76. <a target=xrefwindow id=d32611e1275 href="http://www.ncbi.nlm.nih.gov/pubmed/29188475">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1278 href="https://doi.org/10.1007/s12016-017-8654-z">Publisher Full Text </a></span><div class=note><a name=d32611e1280 class=n-a></a><p class=first id=d32611e1281><a target=xrefwindow href="https://facultyopinions.com/prime/732205165" id=d32611e1282>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d32611e1290 class=n-a></a>Bastuji-Garin S, Rzany B, Stern RS, <i> et al.</i>: Clinical Classification of Cases of Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, and Erythema Multiforme. <i>Arch Dermatol.</i> 1993; <b>129</b>(1): 92–6. <a target=xrefwindow id=d32611e1301 href="http://www.ncbi.nlm.nih.gov/pubmed/8420497">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1304 href="https://doi.org/10.1001/archderm.1993.01680220104023">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d32611e1313 class=n-a></a>Hsu DY, Brieva J, Silverberg NB, <i> et al.</i>: Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. <i>J Invest Dermatol.</i> 2016; <b>136</b>(7): 1387–97. <a target=xrefwindow id=d32611e1324 href="http://www.ncbi.nlm.nih.gov/pubmed/27039263">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1327 href="https://doi.org/10.1016/j.jid.2016.03.023">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d32611e1336 class=n-a></a>Griffiths C, Barker J, Bleiker T, <i> et al.</i>: Rook’s Textbook of Dermatology. 9th ed. Wiley. 2016. <a target=xrefwindow id=d32611e1341 href="https://doi.org/10.1002/9781118441213">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d32611e1350 class=n-a></a>Revuz J, Penso D, Roujeau JC, <i> et al.</i>: Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. <i>Arch Dermatol.</i> 1987; <b>123</b>(9): 1160–5. <a target=xrefwindow id=d32611e1361 href="http://www.ncbi.nlm.nih.gov/pubmed/3632000">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1364 href="https://doi.org/10.1001/archderm.1987.01660330071012">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d32611e1374 class=n-a></a>Bastuji-Garin S, Fouchard N, Bertocchi M, <i> et al.</i>: SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. <i>J Invest Dermatol.</i> 2000; <b>115</b>(2): 149–53. <a target=xrefwindow id=d32611e1385 href="http://www.ncbi.nlm.nih.gov/pubmed/10951229">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1388 href="https://doi.org/10.1046/j.1523-1747.2000.00061.x">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d32611e1397 class=n-a></a>Mockenhaupt M, Viboud C, Dunant A, <i> et al.</i>: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-Study. <i>J Invest Dermatol.</i> 2008; <b>128</b>(1): 35–44. <a target=xrefwindow id=d32611e1408 href="http://www.ncbi.nlm.nih.gov/pubmed/17805350">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1411 href="https://doi.org/10.1038/sj.jid.5701033">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d32611e1420 class=n-a></a>Chung WH, Hung SI, Hong HS, <i> et al.</i>: Medical genetics: A marker for Stevens-Johnson syndrome. <i>Nature.</i> 2004; <b>428</b>(6982): 486. <a target=xrefwindow id=d32611e1431 href="http://www.ncbi.nlm.nih.gov/pubmed/15057820">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1434 href="https://doi.org/10.1038/428486a">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d32611e1443 class=n-a></a>Hung SI, Chung WH, Jee SH, <i> et al.</i>: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. <i>Pharmacogenet Genomics.</i> 2006; <b>16</b>(4): 297–306. <a target=xrefwindow id=d32611e1454 href="http://www.ncbi.nlm.nih.gov/pubmed/16538176">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1457 href="https://doi.org/10.1097/01.fpc.0000199500.46842.4a">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d32611e1466 class=n-a></a>Man CBL, Kwan P, Baum L, <i> et al.</i>: Association between HLA-B*1502 Allele and Antiepileptic Drug-Induced Cutaneous Reactions in Han Chinese. <i>Epilepsia.</i> 2007; <b>48</b>(5): 1015–8. <a target=xrefwindow id=d32611e1477 href="http://www.ncbi.nlm.nih.gov/pubmed/17509004">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1480 href="https://doi.org/10.1111/j.1528-1167.2007.01022.x">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d32611e1489 class=n-a></a>Locharernkul C, Loplumlert J, Limotai C, <i> et al.</i>: Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. <i>Epilepsia.</i> 2008; <b>49</b>(12): 2087–91. <a target=xrefwindow id=d32611e1500 href="http://www.ncbi.nlm.nih.gov/pubmed/18637831">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1503 href="https://doi.org/10.1111/j.1528-1167.2008.01719.x">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d32611e1513 class=n-a></a>Mehta T, Prajapati L, Mittal B, <i> et al.</i>: Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. <i>Indian J Dermatol Venereol Leprol.</i> 2009; <b>75</b>(6): 579–82. <a target=xrefwindow id=d32611e1524 href="http://www.ncbi.nlm.nih.gov/pubmed/19915237">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1527 href="https://doi.org/10.4103/0378-6323.57718">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d32611e1536 class=n-a></a>Ou GJ, Wang J, Ji X, <i> et al.</i>: A study of HLA-B*15: 02 in 9 different Chinese ethnics: Implications for carbamazepine related SJS/TEN. <i>HLA.</i> 2017; <b>89</b>(4): 225–9. <a target=xrefwindow id=d32611e1547 href="http://www.ncbi.nlm.nih.gov/pubmed/28205426">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1550 href="https://doi.org/10.1111/tan.12970">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d32611e1559 class=n-a></a>Khor AHP, Lim KS, Tan CT, <i> et al.</i>: HLA-A*31: 01 and HLA-B*15: 02 association with Stevens-Johnson syndrome and toxic epidermal necrolysis to carbamazepine in a multiethnic Malaysian population. <i>Pharmacogenet Genomics.</i> 2017; <b>27</b>(7): 275–8. <a target=xrefwindow id=d32611e1570 href="http://www.ncbi.nlm.nih.gov/pubmed/28570299">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1573 href="https://doi.org/10.1097/FPC.0000000000000287">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d32611e1582 class=n-a></a>Zhang Y, Wang J, Zhao LM, <i> et al.</i>: Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. <i>Eur J Clin Pharmacol.</i> 2011; <b>67</b>(9): 885–7. <a target=xrefwindow id=d32611e1593 href="http://www.ncbi.nlm.nih.gov/pubmed/21424386">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1596 href="https://doi.org/10.1007/s00228-011-1009-4">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d32611e1605 class=n-a></a>Wu XT, Hu FY, An DM, <i> et al.</i>: Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China. <i>Epilepsy Behav.</i> 2010; <b>19</b>(3): 405–8. <a target=xrefwindow id=d32611e1616 href="http://www.ncbi.nlm.nih.gov/pubmed/20833111">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1619 href="https://doi.org/10.1016/j.yebeh.2010.08.007">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d32611e1628 class=n-a></a>Wang Q, Zhou JQ, Zhou LM, <i> et al.</i>: Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. <i>Seizure.</i> 2011; <b>20</b>(6): 446–8. <a target=xrefwindow id=d32611e1639 href="http://www.ncbi.nlm.nih.gov/pubmed/21397523">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1642 href="https://doi.org/10.1016/j.seizure.2011.02.003">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d32611e1652 class=n-a></a>Tassaneeyakul W, Tiamkao S, Jantararoungtong T, <i> et al.</i>: Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. <i>Epilepsia.</i> 2010; <b>51</b>(5): 926–30. <a target=xrefwindow id=d32611e1663 href="http://www.ncbi.nlm.nih.gov/pubmed/20345939">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1666 href="https://doi.org/10.1111/j.1528-1167.2010.02533.x">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d32611e1675 class=n-a></a>Chang CC, Too CL, Murad S, <i> et al.</i>: Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. <i>Int J Dermatol.</i> 2011; <b>50</b>(2): 221–4. <a target=xrefwindow id=d32611e1686 href="http://www.ncbi.nlm.nih.gov/pubmed/21244392">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1689 href="https://doi.org/10.1111/j.1365-4632.2010.04745.x">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d32611e1698 class=n-a></a>Then SM, Rani ZZM, Raymond AA, <i> et al.</i>: Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. <i>Asian Pac J Allergy Immunol.</i> 2011; <b>29</b>(3): 290–3. <a target=xrefwindow id=d32611e1709 href="http://www.ncbi.nlm.nih.gov/pubmed/22053601">PubMed Abstract </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d32611e1718 class=n-a></a>Hung SI, Chung WH, Liu ZS, <i> et al.</i>: Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. <i>Pharmacogenomics.</i> 2010; <b>11</b>(3): 349–56. <a target=xrefwindow id=d32611e1729 href="http://www.ncbi.nlm.nih.gov/pubmed/20235791">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1732 href="https://doi.org/10.2217/pgs.09.162">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d32611e1741 class=n-a></a>Chen CB, Hsiao YH, Wu T, <i> et al.</i>: Risk and association of <i>HLA</i> with oxcarbazepine-induced cutaneous adverse reactions in Asians. <i>Neurology.</i> 2017; <b>88</b>(1): 78–86. <a target=xrefwindow id=d32611e1755 href="http://www.ncbi.nlm.nih.gov/pubmed/27913699">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1759 href="https://doi.org/10.1212/WNL.0000000000003453">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d32611e1768 class=n-a></a>Chang CC, Ng CC, Too CL, <i> et al.</i>: Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population. <i>Pharmacogenomics J.</i> 2017; <b>17</b>(2): 170–3. <a target=xrefwindow id=d32611e1779 href="http://www.ncbi.nlm.nih.gov/pubmed/26927288">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1782 href="https://doi.org/10.1038/tpj.2016.10">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d32611e1792 class=n-a></a>Shi YW, Min FL, Zhou D, <i> et al.</i>: HLA-A*24:02 as a common risk factor for antiepileptic drug–induced cutaneous adverse reactions. <i>Neurology.</i> 2017; <b>88</b>(23): 2183–91. <a target=xrefwindow id=d32611e1803 href="http://www.ncbi.nlm.nih.gov/pubmed/28476759">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1806 href="https://doi.org/10.1212/WNL.0000000000004008">Publisher Full Text </a> | <a target=xrefwindow id=d32611e1810 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5467955">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d32611e1819 class=n-a></a>Cheung YK, Cheng SH, Chan EJM, <i> et al.</i>: HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. <i>Epilepsia.</i> 2013; <b>54</b>(7): 1307–14. <a target=xrefwindow id=d32611e1830 href="http://www.ncbi.nlm.nih.gov/pubmed/23692434">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1833 href="https://doi.org/10.1111/epi.12217">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d32611e1842 class=n-a></a>Kaniwa N, Saito Y, Aihara M, <i> et al.</i>: HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Pharmacogenomics.</i> 2008; <b>9</b>(11): 1617–22. <a target=xrefwindow id=d32611e1853 href="http://www.ncbi.nlm.nih.gov/pubmed/19018717">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1856 href="https://doi.org/10.2217/14622416.9.11.1617">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d32611e1865 class=n-a></a>Kaniwa N, Saito Y, Aihara M, <i> et al.</i>: <i>HLA-B*1511</i> is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. <i>Epilepsia.</i> 2010; <b>51</b>(12): 2461–5. <a target=xrefwindow id=d32611e1879 href="http://www.ncbi.nlm.nih.gov/pubmed/21204807">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1883 href="https://doi.org/10.1111/j.1528-1167.2010.02766.x">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d32611e1892 class=n-a></a>Park HJ, Kim YJ, Kim DH, <i> et al.</i>: HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs. <i>Yonsei Med J.</i> 2016; <b>57</b>(1): 118–26. <a target=xrefwindow id=d32611e1903 href="http://www.ncbi.nlm.nih.gov/pubmed/26632391">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1906 href="https://doi.org/10.3349/ymj.2016.57.1.118">Publisher Full Text </a> | <a target=xrefwindow id=d32611e1910 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4696942">Free Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d32611e1919 class=n-a></a>Alfirevic A, Jorgensen AL, Williamson PR, <i> et al.</i>: <i>HLA-B</i> locus in Caucasian patients with carbamazepine hypersensitivity. <i>Pharmacogenomics.</i> 2006; <b>7</b>(6): 813–8. <a target=xrefwindow id=d32611e1933 href="http://www.ncbi.nlm.nih.gov/pubmed/16981842">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1937 href="https://doi.org/10.2217/14622416.7.6.813">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d32611e1947 class=n-a></a>Lonjou C, Borot N, Sekula P, <i> et al.</i>: A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. <i>Pharmacogenet Genomics.</i> 2008; <b>18</b>(2): 99–107. <a target=xrefwindow id=d32611e1958 href="http://www.ncbi.nlm.nih.gov/pubmed/18192896">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1961 href="https://doi.org/10.1097/FPC.0b013e3282f3ef9c">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d32611e1970 class=n-a></a>Ramírez E, Bellón T, Tong HY, <i> et al.</i>: Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. <i>Pharmacol Res.</i> 2017; <b>115</b>: 168–178. <a target=xrefwindow id=d32611e1981 href="http://www.ncbi.nlm.nih.gov/pubmed/27888155">PubMed Abstract </a> | <a target=xrefwindow id=d32611e1984 href="https://doi.org/10.1016/j.phrs.2016.11.027">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d32611e1993 class=n-a></a>Kim SH, Lee KW, Song WJ, <i> et al.</i>: Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. <i>Epilepsy Res.</i> 2011; <b>97</b>(1-2): 190–7. <a target=xrefwindow id=d32611e2004 href="http://www.ncbi.nlm.nih.gov/pubmed/21917426">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2007 href="https://doi.org/10.1016/j.eplepsyres.2011.08.010">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d32611e2016 class=n-a></a>Ozeki T, Mushiroda T, Yowang A, <i> et al.</i>: Genome-wide association study identifies <i>HLA-A*3101</i> allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. <i>Hum Mol Genet.</i> 2011; <b>20</b>(5): 1034–41. <a target=xrefwindow id=d32611e2030 href="http://www.ncbi.nlm.nih.gov/pubmed/21149285">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2034 href="https://doi.org/10.1093/hmg/ddq537">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d32611e2043 class=n-a></a>McCormack M, Alfirevic A, Bourgeois S, <i> et al.</i>: HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans. <i>N Engl J Med.</i> 2011; <b>364</b>(12): 1134–43. <a target=xrefwindow id=d32611e2054 href="http://www.ncbi.nlm.nih.gov/pubmed/21428769">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2057 href="https://doi.org/10.1056/NEJMoa1013297">Publisher Full Text </a> | <a target=xrefwindow id=d32611e2061 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3113609">Free Full Text </a></span><div class=note><a name=d32611e2063 class=n-a></a><p class=first id=d32611e2064><a target=xrefwindow href="https://facultyopinions.com/prime/9454964" id=d32611e2065>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d32611e2074 class=n-a></a>Amstutz U, Shear NH, Rieder MJ, <i> et al.</i>: Recommendations for HLA-B*15: 02 and HLA-A*31: 01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. <i>Epilepsia.</i> 2014; <b>55</b>(4): 496–506. <a target=xrefwindow id=d32611e2085 href="http://www.ncbi.nlm.nih.gov/pubmed/24597466">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2088 href="https://doi.org/10.1111/epi.12564">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d32611e2098 class=n-a></a>Ferrell PB, McLeod HL: Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. <i>Pharmacogenomics.</i> 2008; <b>9</b>(10): 1543–6. <a target=xrefwindow id=d32611e2106 href="http://www.ncbi.nlm.nih.gov/pubmed/18855540">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2109 href="https://doi.org/10.2217/14622416.9.10.1543">Publisher Full Text </a> | <a target=xrefwindow id=d32611e2112 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2586963">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d32611e2121 class=n-a></a>Chen P, Lin JJ, Lu CS, <i> et al.</i>: Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. <i>N Engl J Med.</i> 2011; <b>364</b>(12): 1126–33. <a target=xrefwindow id=d32611e2132 href="http://www.ncbi.nlm.nih.gov/pubmed/21428768">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2135 href="https://doi.org/10.1056/NEJMoa1009717">Publisher Full Text </a></span><div class=note><a name=d32611e2137 class=n-a></a><p class=first id=d32611e2138><a target=xrefwindow href="https://facultyopinions.com/prime/11568956" id=d32611e2139>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d32611e2148 class=n-a></a>Hung SI, Chung WH, Liou LB, <i> et al.</i>: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. <i>Proc Natl Acad Sci U S A.</i> 2005; <b>102</b>(11): 4134–9. <a target=xrefwindow id=d32611e2159 href="http://www.ncbi.nlm.nih.gov/pubmed/15743917">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2162 href="https://doi.org/10.1073/pnas.0409500102">Publisher Full Text </a> | <a target=xrefwindow id=d32611e2166 href="http://www.ncbi.nlm.nih.gov/pmc/articles/554812">Free Full Text </a></span><div class=note><a name=d32611e2168 class=n-a></a><p class=first id=d32611e2169><a target=xrefwindow href="https://facultyopinions.com/prime/1088014" id=d32611e2170>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d32611e2179 class=n-a></a>Tassaneeyakul W, Jantararoungtong T, Chen P, <i> et al.</i>: Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. <i>Pharmacogenet Genomics.</i> 2009; <b>19</b>(9): 704–9. <a target=xrefwindow id=d32611e2190 href="http://www.ncbi.nlm.nih.gov/pubmed/19696695">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2193 href="https://doi.org/10.1097/FPC.0b013e328330a3b8">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d32611e2202 class=n-a></a>Niihara H, Kaneko S, Ito T, <i> et al.</i>: HLA-B*58: 01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population. <i>J Dermatol Sci.</i> 2013; <b>71</b>(12): 150–2. <a target=xrefwindow id=d32611e2213 href="http://www.ncbi.nlm.nih.gov/pubmed/23669020">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2216 href="https://doi.org/10.1016/j.jdermsci.2013.04.013">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d32611e2225 class=n-a></a>Cheng L, Xiong Y, Qin CZ, <i> et al.</i>: HLA-B*58: 01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case-control clinical study. <i>Br J Dermatol.</i> 2015; <b>173</b>(2): 555–8. <a target=xrefwindow id=d32611e2236 href="http://www.ncbi.nlm.nih.gov/pubmed/26104483">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2239 href="https://doi.org/10.1111/bjd.13688">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d32611e2249 class=n-a></a>Sukasem C, Jantararoungtong T, Kuntawong P, <i> et al.</i>: <i>HLA-B*58: 01</i> for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand. <i>Front Pharmacol.</i> 2016; <b>7</b>: 186. <a target=xrefwindow id=d32611e2263 href="http://www.ncbi.nlm.nih.gov/pubmed/27486401">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2267 href="https://doi.org/10.3389/fphar.2016.00186">Publisher Full Text </a> | <a target=xrefwindow id=d32611e2270 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4947582">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d32611e2279 class=n-a></a>Gonçalo M, Coutinho I, Teixeira V, <i> et al.</i>: HLA-B*58: 01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population. <i>Br J Dermatol.</i> 2013; <b>169</b>(3): 660–5. <a target=xrefwindow id=d32611e2290 href="http://www.ncbi.nlm.nih.gov/pubmed/23600531">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2293 href="https://doi.org/10.1111/bjd.12389">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d32611e2302 class=n-a></a>Yu KH, Yu CY, Fang YF: Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: An updated systematic review and meta-analysis. <i>Int J Rheum Dis.</i> 2017; <b>20</b>(9): 1057–71. <a target=xrefwindow id=d32611e2310 href="http://www.ncbi.nlm.nih.gov/pubmed/28857441">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2313 href="https://doi.org/10.1111/1756-185X.13143">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d32611e2322 class=n-a></a>Wu R, Cheng YJ, Zhu LL, <i> et al.</i>: Impact of HLA-B*58: 01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies. <i>Oncotarget.</i> 2016; <b>7</b>(49): 81870–9. <a target=xrefwindow id=d32611e2333 href="http://www.ncbi.nlm.nih.gov/pubmed/27835909">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2336 href="https://doi.org/10.18632/oncotarget.13250">Publisher Full Text </a> | <a target=xrefwindow id=d32611e2340 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5348437">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d32611e2349 class=n-a></a>Ke CH, Chung WH, Wen YH, <i> et al.</i>: Cost-effectiveness Analysis for Genotyping Before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions. <i>J Rheumatol.</i> 2017; <b>44</b>(6): 835–43. <a target=xrefwindow id=d32611e2360 href="http://www.ncbi.nlm.nih.gov/pubmed/28365572">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2363 href="https://doi.org/10.3899/jrheum.151476">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d32611e2372 class=n-a></a>Jutkowitz E, Dubreuil M, Lu N, <i> et al.</i>: The Cost-Effectiveness of HLA-B*5801 Screening to Guide Initial Urate-Lowering Therapy for Gout in the United States. <i>Semin Arthritis Rheum.</i> 2017; <b>46</b>(5): 594–600. <a target=xrefwindow id=d32611e2383 href="http://www.ncbi.nlm.nih.gov/pubmed/27916277">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2386 href="https://doi.org/10.1016/j.semarthrit.2016.10.009">Publisher Full Text </a> | <a target=xrefwindow id=d32611e2390 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5403555">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d32611e2400 class=n-a></a>Mallal S, Nolan D, Witt C, <i> et al.</i>: Association Between Presence of <i>HLA-B*5701, HLA-DR7</i>, and <i>HLA-DQ3</i> and Hypersensitivity to HIV-1 Reverse-Transcriptase Inhibitor Abacavir. <i>Lancet.</i> 2002; <b>359</b>: 727–32. <a target=xrefwindow id=d32611e2418 href="http://www.ncbi.nlm.nih.gov/pubmed/11888582">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2421 href="https://doi.org/10.1016/s0140-6736(02)07873-x">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d32611e2430 class=n-a></a>Hetherington S, Hughes AR, Mosteller M, <i> et al.</i>: Genetic Variations in <i>HLA-B</i> Region and Hypersensitivity Reactions to Abacavir. <i>Lancet.</i> 2002; <b>359</b>(9312): 1121–2. <a target=xrefwindow id=d32611e2444 href="http://www.ncbi.nlm.nih.gov/pubmed/11943262">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2448 href="https://doi.org/10.1016/S0140-6736(02)08158-8">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d32611e2457 class=n-a></a>Martin AM, Nolan D, Gaudieri S, <i> et al.</i>: Predisposition to Abacavir Hypersensitivity Conferred by <i>HLA-B*5701</i> and a Haplotypic <i>Hsp70-Hom</i> Variant. <i>Proc Natl Acad Sci U S A.</i> 2004; <b>101</b>(12): 4180–5. <a target=xrefwindow id=d32611e2475 href="http://www.ncbi.nlm.nih.gov/pubmed/15024131">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2478 href="https://doi.org/10.1073/pnas.0307067101">Publisher Full Text </a> | <a target=xrefwindow id=d32611e2481 href="http://www.ncbi.nlm.nih.gov/pmc/articles/384715">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d32611e2490 class=n-a></a>Hughes AR, Mosteller M, Bansal AT, <i> et al.</i>: Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. <i>Pharmacogenomics.</i> 2004; <b>5</b>(2): 203–11. <a target=xrefwindow id=d32611e2501 href="http://www.ncbi.nlm.nih.gov/pubmed/15016610">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2504 href="https://doi.org/10.1517/phgs.5.2.203.27481">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d32611e2513 class=n-a></a>Saag M, Balu R, Phillips E, <i> et al.</i>: High Sensitivity of Human Leukocyte Antigen–B*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients. <i>Clin Infect Dis..</i> 2008; <b>46</b>(7): 1111–8. <a target=xrefwindow id=d32611e2524 href="http://www.ncbi.nlm.nih.gov/pubmed/18444831">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2527 href="https://doi.org/10.1086/529382">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d32611e2536 class=n-a></a>Mallal S, Phillips E, Carosi G, <i> et al.</i>: HLA-B*5701 screening for hypersensitivity to abacavir. <i>N Engl J Med.</i> 2008; <b>358</b>(6): 568–79. <a target=xrefwindow id=d32611e2547 href="http://www.ncbi.nlm.nih.gov/pubmed/18256392">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2550 href="https://doi.org/10.1056/NEJMoa0706135">Publisher Full Text </a></span><div class=note><a name=d32611e2552 class=n-a></a><p class=first id=d32611e2553><a target=xrefwindow href="https://facultyopinions.com/prime/1100304" id=d32611e2554>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d32611e2564 class=n-a></a>Mounzer K, Hsu R, Fusco JS, <i> et al.</i>: HLA-B*57: 01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study. <i>AIDS Res Ther.</i> 2019; <b>16</b>(1): 1. <a target=xrefwindow id=d32611e2575 href="http://www.ncbi.nlm.nih.gov/pubmed/30651100">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2578 href="https://doi.org/10.1186/s12981-019-0217-3">Publisher Full Text </a> | <a target=xrefwindow id=d32611e2582 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6334426">Free Full Text </a></span><div class=note><a name=d32611e2584 class=n-a></a><p class=first id=d32611e2585><a target=xrefwindow href="https://facultyopinions.com/prime/737561396" id=d32611e2586>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d32611e2595 class=n-a></a>Wilkinson GR: Drug metabolism and variability among patients in drug response. <i>N Engl J Med.</i> 2005; <b>352</b>(21): 2211–21. <a target=xrefwindow id=d32611e2603 href="http://www.ncbi.nlm.nih.gov/pubmed/15917386">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2606 href="https://doi.org/10.1056/NEJMra032424">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d32611e2615 class=n-a></a>Chung WH, Chang WC, Lee YS, <i> et al.</i>: Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. <i>JAMA.</i> 2014; <b>312</b>(5): 525–34. <a target=xrefwindow id=d32611e2626 href="http://www.ncbi.nlm.nih.gov/pubmed/25096692">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2629 href="https://doi.org/10.1001/jama.2014.7859">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d32611e2638 class=n-a></a>Pichler WJ: Modes of presentation of chemical neoantigens to the immune system. <i>Toxicology.</i> 2002; <b>181-182</b>: 49–54. <a target=xrefwindow id=d32611e2646 href="http://www.ncbi.nlm.nih.gov/pubmed/12505284">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2649 href="https://doi.org/10.1016/s0300-483x(02)00254-8">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d32611e2658 class=n-a></a>Adam J, Pichler WJ, Yerly D: Delayed drug hypersensitivity: Models of T-cell stimulation. <i>Br J Clin Pharmacol.</i> 2011; <b>71</b>(5): 701–7. <a target=xrefwindow id=d32611e2666 href="http://www.ncbi.nlm.nih.gov/pubmed/21480949">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2669 href="https://doi.org/10.1111/j.1365-2125.2010.03764.x">Publisher Full Text </a> | <a target=xrefwindow id=d32611e2672 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3093075">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d32611e2681 class=n-a></a>Abe R: Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>J Dermatol.</i> 2015; <b>42</b>(1): 42–8. <a target=xrefwindow id=d32611e2689 href="http://www.ncbi.nlm.nih.gov/pubmed/25355273">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2692 href="https://doi.org/10.1111/1346-8138.12674">Publisher Full Text </a></span><div class=note><a name=d32611e2694 class=n-a></a><p class=first id=d32611e2695><a target=xrefwindow href="https://facultyopinions.com/prime/725104495" id=d32611e2696>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d32611e2706 class=n-a></a>Callan HE, Jenkins RE, Maggs JL, <i> et al.</i>: Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: Implications for hapten formation. <i>Chem Res Toxicol.</i> 2009; <b>22</b>(5): 937–48. <a target=xrefwindow id=d32611e2717 href="http://www.ncbi.nlm.nih.gov/pubmed/19358516">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2720 href="https://doi.org/10.1021/tx900034r">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d32611e2729 class=n-a></a>Weltzien HU, Padovan E: Molecular Features of Penicillin Allergy. <i>J Invest Dermatol.</i> 1998; <b>110</b>(3): 203–6. <a target=xrefwindow id=d32611e2737 href="http://www.ncbi.nlm.nih.gov/pubmed/9506435">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2740 href="https://doi.org/10.1046/j.1523-1747.1998.00122.x">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d32611e2749 class=n-a></a>Naisbitt DJ, Hough SJ, Gill HJ, <i> et al.</i>: Cellular disposition of sulphamethoxazole and its metabolites: Implications for hypersensitivity. <i>Br J Pharmacol.</i> 1999; <b>126</b>(6): 1393–407. <a target=xrefwindow id=d32611e2760 href="http://www.ncbi.nlm.nih.gov/pubmed/10217534">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2763 href="https://doi.org/10.1038/sj.bjp.0702453">Publisher Full Text </a> | <a target=xrefwindow id=d32611e2767 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1565922">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d32611e2776 class=n-a></a>Friedmann PS, Lee MS, Friedmann AC, <i> et al.</i>: Mechanisms in cutaneous drug hypersensitivity reactions. <i>Clin Exp Allergy.</i> 2003; <b>33</b>(7): 861–72. <a target=xrefwindow id=d32611e2787 href="http://www.ncbi.nlm.nih.gov/pubmed/12859440">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2790 href="https://doi.org/10.1046/j.1365-2222.2003.01718.x">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d32611e2799 class=n-a></a>Pichler WJ: Pharmacological interaction of drugs with antigen-specific immune receptors: The p-i concept. <i>Curr Opin Allergy Clin Immunol.</i> 2002; <b>2</b>(4): 301–5. <a target=xrefwindow id=d32611e2807 href="http://www.ncbi.nlm.nih.gov/pubmed/12130944">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2810 href="https://doi.org/10.1097/00130832-200208000-00003">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d32611e2819 class=n-a></a>Pichler WJ: Delayed Drug Hypersensitivity Reactions. <i>Ann Intern Med.</i> 2003; <b>139</b>: 683. <a target=xrefwindow id=d32611e2827 href="https://doi.org/10.7326/0003-4819-139-8-200310210-00012">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d32611e2837 class=n-a></a>Yun J, Marcaida MJ, Eriksson KK, <i> et al.</i>: Oxypurinol Directly and Immediately Activates the Drug-Specific T Cells via the Preferential Use of HLA-B*58: 01. <i>J Immunol.</i> 2014; <b>192</b>(7): 2984–93. <a target=xrefwindow id=d32611e2848 href="http://www.ncbi.nlm.nih.gov/pubmed/24591375">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2851 href="https://doi.org/10.4049/jimmunol.1302306">Publisher Full Text </a></span><div class=note><a name=d32611e2853 class=n-a></a><p class=first id=d32611e2854><a target=xrefwindow href="https://facultyopinions.com/prime/718297880" id=d32611e2855>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d32611e2864 class=n-a></a>Pichler WJ, Beeler A, Keller M, <i> et al.</i>: Pharmacological Interaction of Drugs with Immune Receptors: The p-i Concept. <i>Allergol Int.</i> 2006; <b>55</b>(1): 17–25. <a target=xrefwindow id=d32611e2875 href="http://www.ncbi.nlm.nih.gov/pubmed/17075282">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2878 href="https://doi.org/10.2332/allergolint.55.17">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d32611e2887 class=n-a></a>Yang CWO, Hung SI, Juo CG, <i> et al.</i>: HLA-B*1502-bound peptides: Implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. <i>J Allergy Clin Immunol.</i> 2007; <b>120</b>(4): 870–7. <a target=xrefwindow id=d32611e2898 href="http://www.ncbi.nlm.nih.gov/pubmed/17697703">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2901 href="https://doi.org/10.1016/j.jaci.2007.06.017">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d32611e2910 class=n-a></a>Illing PT, Vivian JP, Dudek NL, <i> et al.</i>: Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. <i>Nature.</i> 2012; <b>486</b>(7404): 554–8. <a target=xrefwindow id=d32611e2921 href="http://www.ncbi.nlm.nih.gov/pubmed/22722860">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2924 href="https://doi.org/10.1038/nature11147">Publisher Full Text </a></span><div class=note><a name=d32611e2926 class=n-a></a><p class=first id=d32611e2927><a target=xrefwindow href="https://facultyopinions.com/prime/716748153" id=d32611e2928>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d32611e2937 class=n-a></a>Ostrov DA, Grant BJ, Pompeu YA, <i> et al.</i>: Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. <i>Proc Natl Acad Sci U S A.</i> 2012; <b>109</b>(25): 9959–64. <a target=xrefwindow id=d32611e2948 href="http://www.ncbi.nlm.nih.gov/pubmed/22645359">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2951 href="https://doi.org/10.1073/pnas.1207934109">Publisher Full Text </a> | <a target=xrefwindow id=d32611e2955 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3382472">Free Full Text </a></span><div class=note><a name=d32611e2957 class=n-a></a><p class=first id=d32611e2958><a target=xrefwindow href="https://facultyopinions.com/prime/717347954" id=d32611e2959>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d32611e2968 class=n-a></a>Ko TM, Chung WH, Wei CY, <i> et al.</i>: Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. <i>J Allergy Clin Immunol.</i> 2011; <b>128</b>(6): 1266–1276.e11. <a target=xrefwindow id=d32611e2979 href="http://www.ncbi.nlm.nih.gov/pubmed/21924464">PubMed Abstract </a> | <a target=xrefwindow id=d32611e2982 href="https://doi.org/10.1016/j.jaci.2011.08.013">Publisher Full Text </a></span><div class=note><a name=d32611e2984 class=n-a></a><p class=first id=d32611e2985><a target=xrefwindow href="https://facultyopinions.com/prime/13371086" id=d32611e2986>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d32611e2996 class=n-a></a>Wei CY, Chung WH, Huang HW, <i> et al.</i>: Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. <i>J Allergy Clin Immunol.</i> 2012; <b>129</b>(6): 1562-9.e5. <a target=xrefwindow id=d32611e3007 href="http://www.ncbi.nlm.nih.gov/pubmed/22322005">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3010 href="https://doi.org/10.1016/j.jaci.2011.12.990">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d32611e3019 class=n-a></a>Chung WH, Pan RY, Chu MT, <i> et al.</i>: Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions. <i>J Invest Dermatol.</i> 2015; <b>135</b>(9): 2237–48. <a target=xrefwindow id=d32611e3030 href="http://www.ncbi.nlm.nih.gov/pubmed/25946710">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3033 href="https://doi.org/10.1038/jid.2015.165">Publisher Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d32611e3042 class=n-a></a>Pan RY, Chu MT, Wang CW, <i> et al.</i>: Identification of drug-specific public TCR driving severe cutaneous adverse reactions. <i>Nat Commun.</i> 2019; <b>10</b>(1): 3569. <a target=xrefwindow id=d32611e3053 href="http://www.ncbi.nlm.nih.gov/pubmed/31395875">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3056 href="https://doi.org/10.1038/s41467-019-11396-2">Publisher Full Text </a> | <a target=xrefwindow id=d32611e3060 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6687717">Free Full Text </a></span><div class=note><a name=d32611e3062 class=n-a></a><p class=first id=d32611e3063><a target=xrefwindow href="https://facultyopinions.com/prime/736388498" id=d32611e3064>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d32611e3073 class=n-a></a>Correia O, Delgado L, Ramos JP, <i> et al.</i>: Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. <i>Arch Dermatol.</i> 1993; <b>129</b>(4): 466–8. <a target=xrefwindow id=d32611e3084 href="http://www.ncbi.nlm.nih.gov/pubmed/8466217">PubMed Abstract </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d32611e3093 class=n-a></a>Le Cleach L, Delaire S, Boumsell L, <i> et al.</i>: Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. <i>Clin Exp Immunol.</i> 2000; <b>119</b>(1): 225–30. <a target=xrefwindow id=d32611e3104 href="http://www.ncbi.nlm.nih.gov/pubmed/10606987">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3107 href="https://doi.org/10.1046/j.1365-2249.2000.01119.x">Publisher Full Text </a> | <a target=xrefwindow id=d32611e3111 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1905549">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d32611e3120 class=n-a></a>Tohyama M, Watanabe H, Murakami S, <i> et al.</i>: Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Br J Dermatol.</i> 2012; <b>166</b>(2): 322–30. <a target=xrefwindow id=d32611e3131 href="http://www.ncbi.nlm.nih.gov/pubmed/21936856">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3134 href="https://doi.org/10.1111/j.1365-2133.2011.10649.x">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d32611e3144 class=n-a></a>Correia O, Delgado L, Roujeau JC, <i> et al.</i>: Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: A comparative analysis of serum and blister fluid samples. <i>Arch Dermatol.</i> 2002; <b>138</b>(1): 29–32. <a target=xrefwindow id=d32611e3155 href="http://www.ncbi.nlm.nih.gov/pubmed/11790164">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3158 href="https://doi.org/10.1001/archderm.138.1.29">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d32611e3167 class=n-a></a>Paul C, Wolkenstein P, Adle H, <i> et al.</i>: Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. <i>Br J Dermatol.</i> 1996; <b>134</b>(4): 710–4. <a target=xrefwindow id=d32611e3178 href="http://www.ncbi.nlm.nih.gov/pubmed/8733377">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3181 href="https://doi.org/10.1111/j.1365-2133.1996.tb06976.x">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d32611e3190 class=n-a></a>Elmore S: Apoptosis: A Review of Programmed Cell Death. <i>Toxicol Pathol.</i> 2007; <b>35</b>(4): 495–516. <a target=xrefwindow id=d32611e3198 href="http://www.ncbi.nlm.nih.gov/pubmed/17562483">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3201 href="https://doi.org/10.1080/01926230701320337">Publisher Full Text </a> | <a target=xrefwindow id=d32611e3204 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2117903">Free Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d32611e3213 class=n-a></a>Viard-Leveugle I, Bullani RR, Meda P, <i> et al.</i>: Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions. <i>J Biol Chem.</i> 2003; <b>278</b>(18): 16183–8. <a target=xrefwindow id=d32611e3224 href="http://www.ncbi.nlm.nih.gov/pubmed/12473659">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3227 href="https://doi.org/10.1074/jbc.M212188200">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d32611e3236 class=n-a></a>Viard I, Wehrli P, Bullani R, <i> et al.</i>: Inhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin. <i>Science.</i> 1998; <b>282</b>(5388): 490–3. <a target=xrefwindow id=d32611e3247 href="http://www.ncbi.nlm.nih.gov/pubmed/9774279">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3250 href="https://doi.org/10.1126/science.282.5388.490">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d32611e3259 class=n-a></a>Tanaka M, Suda T, Haze K, <i> et al.</i>: Fas ligand in human serum. <i>Nat Med.</i> 1996; <b>2</b>(3): 317–22. <a target=xrefwindow id=d32611e3270 href="http://www.ncbi.nlm.nih.gov/pubmed/8612231">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3273 href="https://doi.org/10.1038/nm0396-317">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d32611e3283 class=n-a></a>Abe R: Toxic epidermal necrolysis and Stevens-Johnson syndrome: Soluble Fas ligand involvement in the pathomechanisms of these diseases. <i>J Dermatol Sci.</i> 2008; <b>52</b>(3): 151–9. <a target=xrefwindow id=d32611e3291 href="http://www.ncbi.nlm.nih.gov/pubmed/18657400">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3294 href="https://doi.org/10.1016/j.jdermsci.2008.06.003">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d32611e3303 class=n-a></a>Abe R, Shimizu T, Shibaki A, <i> et al.</i>: Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome Are Induced by Soluble Fas Ligand. <i>Am J Pathol.</i> 2003; <b>162</b>(5): 1515–20. <a target=xrefwindow id=d32611e3314 href="http://www.ncbi.nlm.nih.gov/pubmed/12707034">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3317 href="https://doi.org/10.1016/S0002-9440(10)64284-8">Publisher Full Text </a> | <a target=xrefwindow id=d32611e3321 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1851208">Free Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d32611e3330 class=n-a></a>Stur K, Karlhofer FM, Stingl G: Soluble FAS ligand: A discriminating feature between drug-induced skin eruptions and viral exanthemas. <i>J Invest Dermatol.</i> 2007; <b>127</b>(4): 802–7. <a target=xrefwindow id=d32611e3338 href="http://www.ncbi.nlm.nih.gov/pubmed/17139262">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3341 href="https://doi.org/10.1038/sj.jid.5700648">Publisher Full Text </a></span><div class=note><a name=d32611e3343 class=n-a></a><p class=first id=d32611e3344><a target=xrefwindow href="https://facultyopinions.com/prime/1087276" id=d32611e3345>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d32611e3354 class=n-a></a>Nassif A, Bensussan A, Bachot N, <i> et al.</i>: Drug Specific Cytotoxic T-Cells in the Skin Lesions of a Patient with Toxic Epidermal Necrolysis. <i>J Invest Dermatol.</i> 2002; <b>118</b>(4): 728–33. <a target=xrefwindow id=d32611e3365 href="http://www.ncbi.nlm.nih.gov/pubmed/11918724">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3368 href="https://doi.org/10.1046/j.1523-1747.2002.01622.x">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d32611e3377 class=n-a></a>Nassif A, Bensussan A, Boumsell L, <i> et al.</i>: Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells. <i>J Allergy Clin Immunol.</i> 2004; <b>114</b>(5): 1209–15. <a target=xrefwindow id=d32611e3388 href="http://www.ncbi.nlm.nih.gov/pubmed/15536433">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3391 href="https://doi.org/10.1016/j.jaci.2004.07.047">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d32611e3400 class=n-a></a>Chung WH, Hung SI, Yang JY, <i> et al.</i>: Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Nat Med.</i> 2008; <b>14</b>(12): 1343–50. <a target=xrefwindow id=d32611e3411 href="http://www.ncbi.nlm.nih.gov/pubmed/19029983">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3414 href="https://doi.org/10.1038/nm.1884">Publisher Full Text </a></span><div class=note><a name=d32611e3416 class=n-a></a><p class=first id=d32611e3417><a target=xrefwindow href="https://facultyopinions.com/prime/1142856" id=d32611e3418>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d32611e3428 class=n-a></a>Abe R, Yoshioka N, Murata J, <i> et al.</i>: Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. <i>Ann Intern Med.</i> 2009; <b>151</b>(7): 514–5. <a target=xrefwindow id=d32611e3439 href="http://www.ncbi.nlm.nih.gov/pubmed/19805776">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3442 href="https://doi.org/10.7326/0003-4819-151-7-200910060-00016">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d32611e3451 class=n-a></a>Saito N, Abe R, Yoshioka N, <i> et al.</i>: Prolonged elevation of serum granulysin in drug-induced hypersensitivity syndrome. <i>Br J Dermatol.</i> 2012; <b>167</b>(2): 452–3. <a target=xrefwindow id=d32611e3462 href="http://www.ncbi.nlm.nih.gov/pubmed/22384988">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3465 href="https://doi.org/10.1111/j.1365-2133.2012.10921.x">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d32611e3474 class=n-a></a>Saito N, Qiao H, Yanagi T, <i> et al.</i>: An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions. <i>Sci Transl Med.</i> 2014; <b>6</b>(245): 245ra95–245ra95. <a target=xrefwindow id=d32611e3485 href="http://www.ncbi.nlm.nih.gov/pubmed/25031270">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3488 href="https://doi.org/10.1126/scitranslmed.3008227">Publisher Full Text </a></span><div class=note><a name=d32611e3490 class=n-a></a><p class=first id=d32611e3491><a target=xrefwindow href="https://facultyopinions.com/prime/718495399" id=d32611e3492>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d32611e3501 class=n-a></a>Linkermann A, Green DR: Necroptosis. <i>N Engl J Med.</i> 2014; <b>370</b>(5): 455–65. <a target=xrefwindow id=d32611e3509 href="http://www.ncbi.nlm.nih.gov/pubmed/24476434">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3512 href="https://doi.org/10.1056/NEJMra1310050">Publisher Full Text </a> | <a target=xrefwindow id=d32611e3515 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4035222">Free Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d32611e3524 class=n-a></a>Saito N, Yoshioka N, Abe R, <i> et al.</i>: Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients. <i>J Allergy Clin Immunol.</i> 2013; <b>131</b>(2): 434–41.e1-9. <a target=xrefwindow id=d32611e3535 href="http://www.ncbi.nlm.nih.gov/pubmed/23111236">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3538 href="https://doi.org/10.1016/j.jaci.2012.09.014">Publisher Full Text </a></span><div class=note><a name=d32611e3540 class=n-a></a><p class=first id=d32611e3541><a target=xrefwindow href="https://facultyopinions.com/prime/718015948" id=d32611e3542>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d32611e3551 class=n-a></a>Wang F, He D, Tang X, <i> et al.</i>: Chemokine expression in diverse nonimmediate drug hypersensitivity reactions: Focus on thymus activation-regulated chemokine, cutaneous T-cell-attracting chemokine, and interleukin-10. <i>Ann Allergy Asthma Immunol.</i> 2014; <b>113</b>(2): 204–8. <a target=xrefwindow id=d32611e3562 href="http://www.ncbi.nlm.nih.gov/pubmed/24932689">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3565 href="https://doi.org/10.1016/j.anai.2014.05.006">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d32611e3575 class=n-a></a>Wang F, Ye Y, Luo ZY, <i> et al.</i>: Diverse expression of TNF-α and CCL27 in serum and blister of Stevens-Johnson syndrome/toxic epidermal necrolysis. <i>Clin Transl Allergy.</i> 2018; <b>8</b>: 12. <a target=xrefwindow id=d32611e3586 href="http://www.ncbi.nlm.nih.gov/pubmed/29713456">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3589 href="https://doi.org/10.1186/s13601-018-0199-6">Publisher Full Text </a> | <a target=xrefwindow id=d32611e3593 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5909236">Free Full Text </a></span><div class=note><a name=d32611e3595 class=n-a></a><p class=first id=d32611e3596><a target=xrefwindow href="https://facultyopinions.com/prime/733208267" id=d32611e3597>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d32611e3606 class=n-a></a>McCully ML, Moser B: The Human Cutaneous Chemokine System. <i>Front Immunol.</i> 2011; <b>2</b>: 33. <a target=xrefwindow id=d32611e3614 href="http://www.ncbi.nlm.nih.gov/pubmed/22566823">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3617 href="https://doi.org/10.3389/fimmu.2011.00033">Publisher Full Text </a> | <a target=xrefwindow id=d32611e3620 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3342080">Free Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d32611e3629 class=n-a></a>Tapia B, Padial A, Sánchez-Sabaté E, <i> et al.</i>: Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions. <i>J Allergy Clin Immunol.</i> 2004; <b>114</b>(2): 335–40. <a target=xrefwindow id=d32611e3640 href="http://www.ncbi.nlm.nih.gov/pubmed/15316512">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3643 href="https://doi.org/10.1016/j.jaci.2004.04.034">Publisher Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d32611e3652 class=n-a></a>Su SC, Mockenhaupt M, Wolkenstein P, <i> et al.</i>: Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. <i>J Invest Dermatol.</i> 2017; <b>137</b>(5): 1065–73. <a target=xrefwindow id=d32611e3663 href="http://www.ncbi.nlm.nih.gov/pubmed/28011147">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3666 href="https://doi.org/10.1016/j.jid.2016.11.034">Publisher Full Text </a></span><div class=note><a name=d32611e3668 class=n-a></a><p class=first id=d32611e3669><a target=xrefwindow href="https://facultyopinions.com/prime/727142921" id=d32611e3670>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d32611e3679 class=n-a></a>McInnes IB, Leung BP, Sturrock RD, <i> et al.</i>: Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. <i>Nat Med.</i> 1997; <b>3</b>(2): 189–95. <a target=xrefwindow id=d32611e3690 href="http://www.ncbi.nlm.nih.gov/pubmed/9018238">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3693 href="https://doi.org/10.1038/nm0297-189">Publisher Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d32611e3702 class=n-a></a>Hama N, Nishimura K, Hasegawa A, <i> et al.</i>: Galectin-7 as a potential biomarker of Stevens-Johnson syndrome/toxic epidermal necrolysis: Identification by targeted proteomics using causative drug-exposed peripheral blood cells. <i>J Allergy Clin Immunol Pract.</i> 2019; <b>7</b>(8): 2894–2897.e7. <a target=xrefwindow id=d32611e3713 href="http://www.ncbi.nlm.nih.gov/pubmed/31100551">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3716 href="https://doi.org/10.1016/j.jaip.2019.05.002">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d32611e3726 class=n-a></a>Vidova V, Spacil Z: A review on mass spectrometry-based quantitative proteomics: Targeted and data independent acquisition. <i>Anal Chim Acta.</i> 2017; <b>964</b>: 7–23. <a target=xrefwindow id=d32611e3734 href="http://www.ncbi.nlm.nih.gov/pubmed/28351641">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3737 href="https://doi.org/10.1016/j.aca.2017.01.059">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d32611e3746 class=n-a></a>Hasegawa A, Shinkuma S, Hayashi R, <i> et al.</i>: RIP3 as a diagnostic and severity marker for Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>J Allergy Clin Immunol Pract.</i> 2020; <b>8</b>(5): 1768–1771.e7. <a target=xrefwindow id=d32611e3757 href="http://www.ncbi.nlm.nih.gov/pubmed/31954192">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3760 href="https://doi.org/10.1016/j.jaip.2020.01.006">Publisher Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d32611e3769 class=n-a></a>Qing DY, Conegliano D, Shashaty MGS, <i> et al.</i>: Red blood cells induce necroptosis of lung endothelial cells and increase susceptibility to lung inflammation. <i>Am J Respir Crit Care Med.</i> 2014; <b>190</b>(11): 1243–54. <a target=xrefwindow id=d32611e3780 href="http://www.ncbi.nlm.nih.gov/pubmed/25329368">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3783 href="https://doi.org/10.1164/rccm.201406-1095OC">Publisher Full Text </a> | <a target=xrefwindow id=d32611e3787 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4315814">Free Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d32611e3796 class=n-a></a>Shiga S, Cartotto R: What Are the Fluid Requirements in Toxic Epidermal Necrolysis? <i>J Burn Care Res.</i> 2010; <b>31</b>(1): 100–4. <a target=xrefwindow id=d32611e3804 href="http://www.ncbi.nlm.nih.gov/pubmed/20061843">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3807 href="https://doi.org/10.1097/BCR.0b013e3181cb8cb8">Publisher Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d32611e3816 class=n-a></a>Coss-Bu JA, Jefferson LS, Levy ML, <i> et al.</i>: Nutrition requirements in patients with toxic epidermal necrolysis. <i>Nutr Clin Pract.</i> 1997; <b>12</b>(2): 81–4. <a target=xrefwindow id=d32611e3827 href="http://www.ncbi.nlm.nih.gov/pubmed/9155407">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3830 href="https://doi.org/10.1177/011542659701200281">Publisher Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d32611e3839 class=n-a></a>Valeyrie-Allanore L, Ingen-Housz-Oro S, Chosidow O, <i> et al.</i>: French referral center management of Stevens–Johnson syndrome/toxic epidermal necrolysis. <i>Dermatologica Sinica.</i> 2013; <b>31</b>(4): 191–5. <a target=xrefwindow id=d32611e3850 href="https://doi.org/10.1016/j.dsi.2013.09.008">Publisher Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d32611e3860 class=n-a></a>de Prost N, Ingen-Housz-Oro S, Duong Ta, <i> et al.</i>: Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: Epidemiology, risk factors, and predictive value of skin cultures. <i>Medicine (Baltimore).</i> 2010; <b>89</b>(1): 28–36. <a target=xrefwindow id=d32611e3871 href="http://www.ncbi.nlm.nih.gov/pubmed/20075702">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3874 href="https://doi.org/10.1097/MD.0b013e3181ca4290">Publisher Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d32611e3883 class=n-a></a>White KD, Abe R, Ardern-Jones M, <i> et al.</i>: SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. <i>J Allergy Clin Immunol Pract.</i> 2018; <b>6</b>(1): 38–69. <a target=xrefwindow id=d32611e3894 href="http://www.ncbi.nlm.nih.gov/pubmed/29310768">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3897 href="https://doi.org/10.1016/j.jaip.2017.11.023">Publisher Full Text </a> | <a target=xrefwindow id=d32611e3901 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5857362">Free Full Text </a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d32611e3910 class=n-a></a>Zimmermann S, Sekula P, Venhoff M, <i> et al.</i>: Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. <i>JAMA Dermatol.</i> 2017; <b>153</b>(6): 514–22. <a target=xrefwindow id=d32611e3921 href="http://www.ncbi.nlm.nih.gov/pubmed/28329382">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3924 href="https://doi.org/10.1001/jamadermatol.2016.5668">Publisher Full Text </a> | <a target=xrefwindow id=d32611e3928 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5817620">Free Full Text </a></span><div class=note><a name=d32611e3930 class=n-a></a><p class=first id=d32611e3931><a target=xrefwindow href="https://facultyopinions.com/prime/727449569" id=d32611e3932>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d32611e3941 class=n-a></a>Schneider JA, Cohen PR: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. <i>Adv Ther.</i> 2017; <b>34</b>(6): 1235–44. <a target=xrefwindow id=d32611e3949 href="http://www.ncbi.nlm.nih.gov/pubmed/28439852">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3952 href="https://doi.org/10.1007/s12325-017-0530-y">Publisher Full Text </a> | <a target=xrefwindow id=d32611e3955 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5487863">Free Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d32611e3964 class=n-a></a>Creamer D, Walsh SA, Dziewulski P, <i> et al.</i>: U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. <i>Br J Dermatol.</i> 2016; <b>174</b>(6): 1194–227. <a target=xrefwindow id=d32611e3975 href="http://www.ncbi.nlm.nih.gov/pubmed/27317286">PubMed Abstract </a> | <a target=xrefwindow id=d32611e3978 href="https://doi.org/10.1111/bjd.14530">Publisher Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d32611e3987 class=n-a></a>Ginsburg CM: Stevens-Johnson syndrome in children. <i>Pediatr Infect Dis J.</i> 1982; <b>1</b>: 155–8. <a target=xrefwindow id=d32611e3995 href="https://doi.org/10.1097/00006454-198205000-00005">Publisher Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d32611e4005 class=n-a></a>Halebian PH, Corder VJ, Madden MR, <i> et al.</i>: Improved Burn Center Survival of Patients with Toxic Epidermal Necrolysis Managed without Corticosteroids. <i>Ann Surg.</i> 1986; <b>204</b>(5): 503–12. <a target=xrefwindow id=d32611e4016 href="http://www.ncbi.nlm.nih.gov/pubmed/3767483">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4019 href="https://doi.org/10.1097/00000658-198611000-00001">Publisher Full Text </a> | <a target=xrefwindow id=d32611e4023 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1251332">Free Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d32611e4032 class=n-a></a>Kelemen JJ 3rd, Cioffi WG, McManus WF, <i> et al.</i>: Burn center care for patients with toxic epidermal necrolysis. <i>J Am Coll Surg.</i> 1995; <b>180</b>(3): 273–8. <a target=xrefwindow id=d32611e4043 href="http://www.ncbi.nlm.nih.gov/pubmed/7874336">PubMed Abstract </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d32611e4052 class=n-a></a>Finkelstein Y, Soon GS, Acuna P, <i> et al.</i>: Recurrence and Outcomes of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children. <i>Pediatrics.</i> 2011; <b>128</b>(4): 723–8. <a target=xrefwindow id=d32611e4063 href="http://www.ncbi.nlm.nih.gov/pubmed/21890829">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4066 href="https://doi.org/10.1542/peds.2010-3322">Publisher Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d32611e4075 class=n-a></a>Sekula P, Dunant A, Mockenhaupt M, <i> et al.</i>: Comprehensive Survival Analysis of a Cohort of Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>J Invest Dermatol.</i> 2013; <b>133</b>(5): 1197–204. <a target=xrefwindow id=d32611e4086 href="http://www.ncbi.nlm.nih.gov/pubmed/23389396">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4089 href="https://doi.org/10.1038/jid.2012.510">Publisher Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d32611e4098 class=n-a></a>Roujeau JC, Bastuji-Garin S: Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality. <i>Ther Adv Drug Saf.</i> 2011; <b>2</b>(3): 87–94. <a target=xrefwindow id=d32611e4106 href="http://www.ncbi.nlm.nih.gov/pubmed/25083204">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4109 href="https://doi.org/10.1177/2042098611404094">Publisher Full Text </a> | <a target=xrefwindow id=d32611e4112 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4110817">Free Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d32611e4121 class=n-a></a>Schneck J, Fagot JP, Sekula P, <i> et al.</i>: Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. <i>J Am Acad Dermatol.</i> 2008; <b>58</b>(1): 33–40. <a target=xrefwindow id=d32611e4132 href="http://www.ncbi.nlm.nih.gov/pubmed/17919775">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4135 href="https://doi.org/10.1016/j.jaad.2007.08.039">Publisher Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d32611e4145 class=n-a></a>Kardaun SH, Jonkman MF: Dexamethasone Pulse Therapy for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. <i>Acta Derm Venereol.</i> 2007; <b>87</b>(2): 144–8. <a target=xrefwindow id=d32611e4153 href="http://www.ncbi.nlm.nih.gov/pubmed/17340021">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4156 href="https://doi.org/10.2340/00015555-0214">Publisher Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d32611e4165 class=n-a></a>Lee HY, Lim YL, Thirumoorthy T, <i> et al.</i>: The role of intravenous immunoglobulin in toxic epidermal necrolysis: A retrospective analysis of 64 patients managed in a specialized centre. <i>Br J Dermatol.</i> 2013; <b>169</b>(6): 1304–9. <a target=xrefwindow id=d32611e4176 href="http://www.ncbi.nlm.nih.gov/pubmed/24007192">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4179 href="https://doi.org/10.1111/bjd.12607">Publisher Full Text </a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d32611e4188 class=n-a></a>Bachot N, Revuz J, Roujeau JC: Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: A prospective noncomparative study showing no benefit on mortality or progression. <i>Arch Dermatol.</i> 2003; <b>139</b>(1): 33–6. <a target=xrefwindow id=d32611e4196 href="http://www.ncbi.nlm.nih.gov/pubmed/12533161">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4199 href="https://doi.org/10.1001/archderm.139.1.33">Publisher Full Text </a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d32611e4208 class=n-a></a>Brown KM, Silver GM, Halerz M, <i> et al.</i>: Toxic epidermal necrolysis: Does immunoglobulin make a difference? <i>J Burn Care Rehabil.</i> 2004; <b>25</b>(1): 81–8. <a target=xrefwindow id=d32611e4219 href="http://www.ncbi.nlm.nih.gov/pubmed/14726744">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4222 href="https://doi.org/10.1097/01.BCR.0000105096.93526.27">Publisher Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d32611e4231 class=n-a></a>Huang YC, Li YC, Chen TJ: The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: A systematic review and meta-analysis. <i>Br J Dermatol.</i> 2012; <b>167</b>(2): 424–32. <a target=xrefwindow id=d32611e4239 href="http://www.ncbi.nlm.nih.gov/pubmed/22458671">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4242 href="https://doi.org/10.1111/j.1365-2133.2012.10965.x">Publisher Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d32611e4251 class=n-a></a>Metry DW, Jung P, Levy ML: Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: Seven cases and review of the literature. <i>Pediatrics.</i> 2003; <b>112</b>(6 Pt 1): 1430–6. <a target=xrefwindow id=d32611e4259 href="http://www.ncbi.nlm.nih.gov/pubmed/14654625">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4262 href="https://doi.org/10.1542/peds.112.6.1430">Publisher Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d32611e4272 class=n-a></a>Prins C, Vittorio C, Padilla RS, <i> et al.</i>: Effect of High-Dose Intravenous Immunoglobulin Therapy in Stevens-Johnson Syndrome: A Retrospective, Multicenter Study. <i>Dermatology.</i> 2003; <b>207</b>(1): 96–9. <a target=xrefwindow id=d32611e4283 href="http://www.ncbi.nlm.nih.gov/pubmed/12835566">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4286 href="https://doi.org/10.1159/000070957">Publisher Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d32611e4295 class=n-a></a>Faye O, Roujeau JC: Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): Clinical experience to date. <i>Drugs.</i> 2005; <b>65</b>(15): 2085–90. <a target=xrefwindow id=d32611e4303 href="http://www.ncbi.nlm.nih.gov/pubmed/16225365">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4306 href="https://doi.org/10.2165/00003495-200565150-00002">Publisher Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d32611e4315 class=n-a></a>Morici MV, Galen WK, Shetty AK, <i> et al.</i>: Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. <i>J Rheumatol.</i> 2000; <b>27</b>(10): 2494–7. <a target=xrefwindow id=d32611e4326 href="http://www.ncbi.nlm.nih.gov/pubmed/11036849">PubMed Abstract </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d32611e4335 class=n-a></a>Barron SJ, Del Vecchio MT, Aronoff SC: Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: A meta-analysis with meta-regression of observational studies. <i>Int J Dermatol.</i> 2015; <b>54</b>(1): 108–15. <a target=xrefwindow id=d32611e4343 href="http://www.ncbi.nlm.nih.gov/pubmed/24697283">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4346 href="https://doi.org/10.1111/ijd.12423">Publisher Full Text </a></span><div class=note><a name=d32611e4348 class=n-a></a><p class=first id=d32611e4349><a target=xrefwindow href="https://facultyopinions.com/prime/718338668" id=d32611e4350>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d32611e4359 class=n-a></a>Chung WH, Wang CW, Dao RL: Severe cutaneous adverse drug reactions. <i>J Dermatol.</i> 2016; <b>43</b>(7): 758–66. <a target=xrefwindow id=d32611e4367 href="http://www.ncbi.nlm.nih.gov/pubmed/27154258">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4370 href="https://doi.org/10.1111/1346-8138.13430">Publisher Full Text </a></span><div class=note><a name=d32611e4372 class=n-a></a><p class=first id=d32611e4373><a target=xrefwindow href="https://facultyopinions.com/prime/726339602" id=d32611e4374>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d32611e4383 class=n-a></a>Valeyrie-Allanore L, Wolkenstein P, Brochard L, <i> et al.</i>: Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Br J Dermatol.</i> 2010; <b>163</b>(4): 847–53. <a target=xrefwindow id=d32611e4394 href="http://www.ncbi.nlm.nih.gov/pubmed/20500799">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4397 href="https://doi.org/10.1111/j.1365-2133.2010.09863.x">Publisher Full Text </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a name=d32611e4407 class=n-a></a>Kirchhof MG, Miliszewski MA, Sikora S, <i> et al.</i>: Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. <i>J Am Acad Dermatol.</i> 2014; <b>71</b>(5): 941–7. <a target=xrefwindow id=d32611e4418 href="http://www.ncbi.nlm.nih.gov/pubmed/25087214">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4421 href="https://doi.org/10.1016/j.jaad.2014.07.016">Publisher Full Text </a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a name=d32611e4430 class=n-a></a>Kumar P, Das NK: Cyclosporine in toxic epidermal necrolysis: A brief review of the emerging therapeutic modality. <i>Dermatol Online J.</i> 2016; <b>22</b>(10): 13030/qt3m82s074. <a target=xrefwindow id=d32611e4438 href="http://www.ncbi.nlm.nih.gov/pubmed/28329582">PubMed Abstract </a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a name=d32611e4447 class=n-a></a>Lee HY, Fook-Chong S, Koh HY, <i> et al.</i>: Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center. <i>J Am Acad Dermatol.</i> 2017; <b>76</b>(1) 106–113. <a target=xrefwindow id=d32611e4458 href="http://www.ncbi.nlm.nih.gov/pubmed/27717620">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4461 href="https://doi.org/10.1016/j.jaad.2016.07.048">Publisher Full Text </a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a name=d32611e4470 class=n-a></a>Ng QX, de Deyn MLZQ, Venkatanarayanan N, <i> et al.</i>: A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis. <i>J Inflamm Res.</i> 2018; <b>11</b>: 135–142. <a target=xrefwindow id=d32611e4481 href="http://www.ncbi.nlm.nih.gov/pubmed/29636627">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4484 href="https://doi.org/10.2147/JIR.S160964">Publisher Full Text </a> | <a target=xrefwindow id=d32611e4488 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5880515">Free Full Text </a></span><div class=note><a name=d32611e4490 class=n-a></a><p class=first id=d32611e4491><a target=xrefwindow href="https://facultyopinions.com/prime/733070892" id=d32611e4492>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a name=d32611e4501 class=n-a></a>González-Herrada C, Rodríguez-Martín S, Cachafeiro L, <i> et al.</i>: Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches. <i>J Invest Dermatol.</i> 2017; <b>137</b>(10): 2092–100. <a target=xrefwindow id=d32611e4512 href="http://www.ncbi.nlm.nih.gov/pubmed/28634032">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4515 href="https://doi.org/10.1016/j.jid.2017.05.022">Publisher Full Text </a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a name=d32611e4524 class=n-a></a>Roujeau J-C, Mockenhaupt M, Guillaume J-C, <i> et al.</i>: New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis. <i>J Invest Dermatol.</i> 2017; <b>137</b>(10): 2047–9. <a target=xrefwindow id=d32611e4535 href="http://www.ncbi.nlm.nih.gov/pubmed/28941473">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4538 href="https://doi.org/10.1016/j.jid.2017.07.828">Publisher Full Text </a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a name=d32611e4548 class=n-a></a>Shah R, Chen ST, Kroshinsky D: Use of Cyclosporine for the treatment of Steven Johnson Syndrome/ Toxic Epidermal Necrolysis. <i>J Am Acad Dermatol.</i> 2019; S0190–9622(19)30001-5. <a target=xrefwindow id=d32611e4553 href="http://www.ncbi.nlm.nih.gov/pubmed/30630021">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4556 href="https://doi.org/10.1016/j.jaad.2018.09.063">Publisher Full Text </a></span><div class=note><a name=d32611e4558 class=n-a></a><p class=first id=d32611e4559><a target=xrefwindow href="https://facultyopinions.com/prime/736084980" id=d32611e4560>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a name=d32611e4569 class=n-a></a>Gilbert M, Scherrer LA: Efficacy and safety of cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Dermatol Ther.</i> 2019; <b>32</b>(1): e12758. <a target=xrefwindow id=d32611e4577 href="http://www.ncbi.nlm.nih.gov/pubmed/30285308">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4580 href="https://doi.org/10.1111/dth.12758">Publisher Full Text </a></span><div class=note><a name=d32611e4582 class=n-a></a><p class=first id=d32611e4583><a target=xrefwindow href="https://facultyopinions.com/prime/734157772" id=d32611e4584>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a name=d32611e4593 class=n-a></a>Kamanabroo D, Schmitz-Landgraf W, Czarnetzki BM: Plasmapheresis in Severe Drug-Induced Toxic Epidermal Necrolysis. <i>Arch Dermatol.</i> 1985; <b>121</b>(12): 1548–1549. <a target=xrefwindow id=d32611e4601 href="http://www.ncbi.nlm.nih.gov/pubmed/4062337">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4604 href="https://doi.org/10.1001/archderm.1985.01660120074023">Publisher Full Text </a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a name=d32611e4613 class=n-a></a>Sakellariou G, Koukoudis P, Karpouzas J, <i> et al.</i>: Plasma Exchange (Pe) Treatment in Drug-Induced Toxic Epidermal Necrolysis (Ten). <i>Int J Artif Organs.</i> 1991; <b>14</b>(10): 634–8. <a target=xrefwindow id=d32611e4624 href="http://www.ncbi.nlm.nih.gov/pubmed/1748531">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4627 href="https://doi.org/10.1177/039139889101401006">Publisher Full Text </a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a name=d32611e4636 class=n-a></a>Chaidemenos GC, Chrysomallis F, Sombolos K, <i> et al.</i>: Plasmapheresis in toxic epidermal necrolysis. <i>Int J Dermatol.</i> 1997; <b>36</b>(3): 218–21. <a target=xrefwindow id=d32611e4647 href="http://www.ncbi.nlm.nih.gov/pubmed/9159011">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4650 href="https://doi.org/10.1046/j.1365-4362.1997.00192.x">Publisher Full Text </a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a name=d32611e4659 class=n-a></a>Egan CA, Grant WJ, Morris SE, <i> et al.</i>: Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. <i>J Am Acad Dermatol.</i> 1999; <b>40</b>(3): 458–61. <a target=xrefwindow id=d32611e4670 href="http://www.ncbi.nlm.nih.gov/pubmed/10071318">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4673 href="https://doi.org/10.1016/s0190-9622(99)70497-4">Publisher Full Text </a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d32611e4683 class=n-a></a>Bamichas G, Natse T, Christidou F, <i> et al.</i>: Plasma exchange in patients with toxic epidermal necrolysis. <i>Ther Apher.</i> 2002; <b>6</b>(3): 225–8. <a target=xrefwindow id=d32611e4694 href="http://www.ncbi.nlm.nih.gov/pubmed/12109948">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4697 href="https://doi.org/10.1046/j.1526-0968.2002.00409.x">Publisher Full Text </a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a name=d32611e4706 class=n-a></a>Yamada H, Takamori K, Yaguchi H, <i> et al.</i>: A Study of the Efficacy of Plasmapheresis for the Treatment of Drug Induced Toxic Epidermal Necrolysis. <i>Ther Apher.</i> 1998; <b>2</b>(2): 153–6. <a target=xrefwindow id=d32611e4717 href="http://www.ncbi.nlm.nih.gov/pubmed/10225718">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4720 href="https://doi.org/10.1111/j.1744-9987.1998.tb00094.x">Publisher Full Text </a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a name=d32611e4729 class=n-a></a>Furubacke A, Berlin G, Anderson C, <i> et al.</i>: Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis? <i>Intensive Care Med.</i> 1999; <b>25</b>(11): 1307–10. <a target=xrefwindow id=d32611e4740 href="http://www.ncbi.nlm.nih.gov/pubmed/10654219">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4743 href="https://doi.org/10.1007/s001340051063">Publisher Full Text </a></span></li><li><a name=ref-147 class=n-a></a><span class=label>147. </span>&nbsp;<span class=citation><a name=d32611e4752 class=n-a></a>Narita YM, Hirahara K, Mizukawa Y, <i> et al.</i>: Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: Is cytokine expression analysis useful in predicting its therapeutic efficacy? <i>J Dermatol.</i> 2011; <b>38</b>(3): 236–45. <a target=xrefwindow id=d32611e4763 href="http://www.ncbi.nlm.nih.gov/pubmed/21342225">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4766 href="https://doi.org/10.1111/j.1346-8138.2010.01154.x">Publisher Full Text </a></span></li><li><a name=ref-148 class=n-a></a><span class=label>148. </span>&nbsp;<span class=citation><a name=d32611e4775 class=n-a></a>Lissia M, Figus A, Rubino C: Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: Preliminary report. <i>Br J Plast Surg.</i> 2005; <b>58</b>(4): 504–10. <a target=xrefwindow id=d32611e4783 href="http://www.ncbi.nlm.nih.gov/pubmed/15897036">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4786 href="https://doi.org/10.1016/j.bjps.2004.12.007">Publisher Full Text </a></span></li><li><a name=ref-149 class=n-a></a><span class=label>149. </span>&nbsp;<span class=citation><a name=d32611e4795 class=n-a></a>Han F, Zhang J, Guo Q, <i> et al.</i>: Successful treatment of toxic epidermal necrolysis using plasmapheresis: A prospective observational study. <i>J Crit Care.</i> 2017; <b>42</b>: 65–8. <a target=xrefwindow id=d32611e4806 href="http://www.ncbi.nlm.nih.gov/pubmed/28688239">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4809 href="https://doi.org/10.1016/j.jcrc.2017.07.002">Publisher Full Text </a></span><div class=note><a name=d32611e4811 class=n-a></a><p class=first id=d32611e4812><a target=xrefwindow href="https://facultyopinions.com/prime/727788499" id=d32611e4813>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-150 class=n-a></a><span class=label>150. </span>&nbsp;<span class=citation><a name=d32611e4823 class=n-a></a>Paquet P, Nikkels A, Arrese JE, <i> et al.</i>: Macrophages and Tumor Necrosis Factor Alpha in Toxic Epidermal Necrolysis. <i>Arch Dermatol.</i> 1994; <b>130</b>(5): 605–8. <a target=xrefwindow id=d32611e4834 href="http://www.ncbi.nlm.nih.gov/pubmed/8179342">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4837 href="https://doi.org/10.1001/archderm.1994.01690050073012">Publisher Full Text </a></span></li><li><a name=ref-151 class=n-a></a><span class=label>151. </span>&nbsp;<span class=citation><a name=d32611e4846 class=n-a></a>Nassif A, Moslehi H, Le Gouvello S, <i> et al.</i>: Evaluation of the potential role of cytokines in toxic epidermal necrolysis. <i>J Invest Dermatol.</i> 2004; <b>123</b>(5): 850–5. <a target=xrefwindow id=d32611e4857 href="http://www.ncbi.nlm.nih.gov/pubmed/15482470">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4860 href="https://doi.org/10.1111/j.0022-202X.2004.23439.x">Publisher Full Text </a></span></li><li><a name=ref-152 class=n-a></a><span class=label>152. </span>&nbsp;<span class=citation><a name=d32611e4869 class=n-a></a>Wojtkiewicz A, Wysocki M, Fortuna J, <i> et al.</i>: Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. <i>Acta Derm Venereol.</i> 2008; <b>88</b>(4): 420–1. <a target=xrefwindow id=d32611e4880 href="http://www.ncbi.nlm.nih.gov/pubmed/18709327">PubMed Abstract </a></span></li><li><a name=ref-153 class=n-a></a><span class=label>153. </span>&nbsp;<span class=citation><a name=d32611e4889 class=n-a></a>Patmanidis K, Sidiras A, Dolianitis K, <i> et al.</i>: Combination of infliximab and high-dose intravenous immunoglobulin for toxic epidermal necrolysis: Successful treatment of an elderly patient. <i>Case Rep Dermatol Med.</i> 2012; <b>2012</b>: 915314. <a target=xrefwindow id=d32611e4900 href="http://www.ncbi.nlm.nih.gov/pubmed/23259092">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4903 href="https://doi.org/10.1155/2012/915314">Publisher Full Text </a> | <a target=xrefwindow id=d32611e4907 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3505931">Free Full Text </a></span></li><li><a name=ref-154 class=n-a></a><span class=label>154. </span>&nbsp;<span class=citation><a name=d32611e4916 class=n-a></a>Zárate-Correa LC, Carrillo-Gómez DC, Ramírez-Escobar AF, <i> et al.</i>: Toxic epidermal necrolysis successfully treated with infliximab. <i>J Investig Allergol Clin Immunol.</i> 2013; <b>23</b>(1): 61–3. <a target=xrefwindow id=d32611e4927 href="http://www.ncbi.nlm.nih.gov/pubmed/23653980">PubMed Abstract </a></span></li><li><a name=ref-155 class=n-a></a><span class=label>155. </span>&nbsp;<span class=citation><a name=d32611e4936 class=n-a></a>Scott-Lang V, Tidman M, McKay D: Toxic Epidermal Necrolysis in a Child Successfully Treated with Infliximab. <i>Pediatr Dermatol.</i> 2014; <b>31</b>(4): 532–4. <a target=xrefwindow id=d32611e4944 href="http://www.ncbi.nlm.nih.gov/pubmed/23072342">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4947 href="https://doi.org/10.1111/pde.12029">Publisher Full Text </a></span></li><li><a name=ref-156 class=n-a></a><span class=label>156. </span>&nbsp;<span class=citation><a name=d32611e4957 class=n-a></a>Pham CH, Gillenwater TJ, Nagengast E, <i> et al.</i>: Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis. <i>Burns.</i> 2019; <b>45</b>(7): 1634–1638. <a target=xrefwindow id=d32611e4968 href="http://www.ncbi.nlm.nih.gov/pubmed/31466921">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4971 href="https://doi.org/10.1016/j.burns.2018.12.018">Publisher Full Text </a></span><div class=note><a name=d32611e4973 class=n-a></a><p class=first id=d32611e4974><a target=xrefwindow href="https://facultyopinions.com/prime/736554834" id=d32611e4975>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-157 class=n-a></a><span class=label>157. </span>&nbsp;<span class=citation><a name=d32611e4984 class=n-a></a>Paradisi A, Abeni D, Bergamo F, <i> et al.</i>: Etanercept therapy for toxic epidermal necrolysis. <i>J Am Acad Dermatol.</i> 2014; <b>71</b>(2): 278–83. <a target=xrefwindow id=d32611e4995 href="http://www.ncbi.nlm.nih.gov/pubmed/24928706">PubMed Abstract </a> | <a target=xrefwindow id=d32611e4998 href="https://doi.org/10.1016/j.jaad.2014.04.044">Publisher Full Text </a></span></li><li><a name=ref-158 class=n-a></a><span class=label>158. </span>&nbsp;<span class=citation><a name=d32611e5007 class=n-a></a>Hunger RE, Hunziker T, Buettiker U, <i> et al.</i>: Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. <i>J Allergy Clin Immunol.</i> 2005; <b>116</b>(4): 923–4. <a target=xrefwindow id=d32611e5018 href="http://www.ncbi.nlm.nih.gov/pubmed/16210071">PubMed Abstract </a> | <a target=xrefwindow id=d32611e5021 href="https://doi.org/10.1016/j.jaci.2005.06.029">Publisher Full Text </a></span></li><li><a name=ref-159 class=n-a></a><span class=label>159. </span>&nbsp;<span class=citation><a name=d32611e5030 class=n-a></a>Gubinelli E, Canzona F, Tonanzi T, <i> et al.</i>: Toxic epidermal necrolysis successfully treated with etanercept. <i>J Dermatol.</i> 2009; <b>36</b>(3): 150–3. <a target=xrefwindow id=d32611e5041 href="http://www.ncbi.nlm.nih.gov/pubmed/19335689">PubMed Abstract </a> | <a target=xrefwindow id=d32611e5044 href="https://doi.org/10.1111/j.1346-8138.2009.00616.x">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 16 Jun 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-612&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-612&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan<br/> <p> <div class=margin-bottom> Akito Hasegawa <br/> <span>Roles: </span> Conceptualization, Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Riichiro Abe <br/> <span>Roles: </span> Data Curation, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-612/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 16 Jun 2020, 9:612 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.24748.1">https://doi.org/10.12688/f1000research.24748.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Hasegawa A and Abe R. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=27302 data-id=24748 data-downloads="" data-views="" data-scholar="10.12688/f1000research.24748.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-612/v1/pdf?article_uuid=ac77206c-0eeb-4edf-b864-23c5086eab69" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.24748.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Hasegawa A and Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis [version 1; peer review: 2 approved] <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):612 (<a href="https://doi.org/10.12688/f1000research.24748.1" target=_blank>https://doi.org/10.12688/f1000research.24748.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=24748 id=mobile-track-article-signin-24748 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/24748?target=/articles/9-612"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=27302 /> <input name=articleId type=hidden value=24748 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Marc Vocanson</strong>, CIRI, International Center for Infectiology Research, Université de Lyon, France; CIRI-INSERM U1111, France </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Julia Spoendlin</strong>, Basel Pharmacoepidemiology Unit, Department of Pharmaceutical Sciences, University of Basel, Switzerland </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 16 Jun 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-612&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-612&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=68826-64515></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=68825-64514></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/9-612/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>16 Jun 20</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Marc Vocanson</strong>, CIRI, International Center for Infectiology Research, Université de Lyon, France; CIRI-INSERM U1111, France </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Julia Spoendlin</strong>, Basel Pharmacoepidemiology Unit, Department of Pharmaceutical Sciences, University of Basel, Switzerland </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-612&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-612/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in managing and understanding...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-612/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-612/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-612/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Hasegawa A and Abe R');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-612/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-612",
            templates : {
                twitter : "Recent advances in managing and understanding Stevens-Johnson.... Hasegawa A and Abe R, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-612/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/24748/27302")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "27302");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "64514": 0,
                           "64515": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "30c10397-a6fa-444e-9ec6-e51835f3bcfd";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-612.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-612.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-612.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-612.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-612.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>